Clinical Deep Dives is a Medlock Holmes podcast for clinicians and learners who want understanding, not just information. Using classic medical and surgical texts as a guide and the generative power of AI, each episode explores ideas with curiosity and clarity, designed for learning on the move and knowledge that actually sticks.
Découvrez des podcasts liées à Clinical Deep Dives. Explorez des podcasts avec des thèmes, sujets, et formats similaires. Ces similarités sont calculées grâce à des données tangibles, pas d'extrapolations !
Medlock Holmes enters The Last Ward, a quiet wing of the hospital where medicine appears to be running out of doors.
Behind the patients lie operating theatres, chemotherapy suites, dialysis machines and intensive-care units. Ahead lies a doorway that medicine cannot ultimately prevent anyone from reaching.
But Holmes immediately notices something important.
The doctors have not disappeared.
Neither has psychiatry.
Because when cure becomes impossible, there remains an enormous amount to treat.
PAIN • FATIGUE • ANXIETY • DEPRESSION • DELIRIUM • FEAR • CONFLICT • LONELINESS • LOSS • MEANING
The central transition in terminal care is therefore not:
TREATMENT → NO TREATMENT
It is:
CURE-FOCUSED CARE → COMFORT-FOCUSED CARE
The goals change.
Instead of asking only, How can we prolong life?, clinicians increasingly ask:
How can this person live as well as possible within the life that remains?
This is where psychiatry becomes particularly important.
Dying is simultaneously biological, psychological, relational, cultural, spiritual and existential. The psychiatrist therefore works not simply with a diagnosis but with an entire human system:
PATIENT ↔ FAMILY ↔ MEDICAL TEAM
Holmes first encounters pain.
Pain is physical, but suffering is larger than pain. Anxiety can intensify pain. Depression can reduce tolerance of it. Fear may magnify bodily sensations. Family distress can increase the patient’s distress. Poor communication can leave symptoms undertreated.
The psychiatrist can therefore help the team understand that effective pain management requires attention to both physiology and meaning.
Beside pain lies fatigue, one of the most pervasive symptoms of advanced illness. It may contain physical, cognitive, emotional and motivational components. Disease, anaemia, medication, malnutrition, sleep disturbance and depression may all contribute.
The mistake is to force fatigue into a false choice:
PHYSICAL OR PSYCHOLOGICAL?
In terminal illness, it is frequently both.
Holmes then enters the room of anxiety.
Dying patients may experience fear of pain, breathlessness, dependency, separation, abandonment, loss of control or death itself. Anxiety may appear as restlessness, insomnia, nausea, tremor, tachycardia or shortness of breath rather than as the word anxiety.
Some fears can be treated.
Others must be understood.
A person frightened of dying does not necessarily have an anxiety disorder.
The psychiatrist’s task is not to pathologise mortality.
It is to identify when understandable fear has become overwhelming, when physical illness or medication is contributing, and what can realistically be relieved.
Then comes depression, one of the most difficult diagnostic problems in terminal illness.
Many ordinary depressive criteria overlap with advanced disease:
Sadness about approaching death is understandable.
Major depression is not an inevitable part of dying.
And treating depression may matter enormously even when life expectancy is short.
When there is sufficient time, antidepressants may help. When time is limited and rapid improvement in energy, alertness or engagement is particularly valuable, carefully selected psychostimulants may sometimes have a role.
The treatment goal may be extraordinarily human:
enough energy to speak with one’s children, complete unfinished conversations or remain emotionally present with loved ones.
Holmes then encounters the most chaotic room in the ward.
The clocks show different times. Shadows move across the walls. The patient cannot recognise where they are.
This is delirium.
Delirium becomes increasingly common as advanced illness progresses and is particularly frequent near death. Causes may include medications, dehydration, infection, metabolic abnormalities, organ failure, hypoxia and the underlying disease itself. Often several causes coexist.
The clinical question changes according to the goals of care.
Earlier in illness, extensive investigation may be appropriate.
Near death, the psychiatrist asks:
Will finding and treating this cause meaningfully improve comfort without imposing disproportionate burden?
Potentially reversible causes should still be considered, particularly medication effects and dehydration. But invasive investigations may themselves become inconsistent with the patient’s goals.
The environment also matters: familiar people, orientation cues, reduced disruption, sleep, calm surroundings and continuity of care can reduce distress.
Holmes then reaches the family room.
Here he discovers that terminal illness rarely belongs to one person.
Families experience anticipatory grief, exhaustion, guilt, anger and uncertainty. Old conflicts may return. Different relatives may disagree about treatment. One may demand that everything possible be done while another believes continuing treatment is prolonging suffering.
And sometimes the patient can no longer decide.
Now medicine enters the complex territory of capacity, advance directives and surrogate decision-making.
The central question becomes:
What would this person have wanted?
Advance care planning can make that answer clearer.
But surrogate decision-making carries a substantial psychological burden. Families may remain uncertain whether they made the right decision long after the patient has died.
The psychiatrist may therefore help not by deciding for them, but by clarifying values, reducing conflict, improving communication and helping everyone return to the patient’s preferences and interests.
Then Holmes encounters another fundamental distinction:
WITHHOLDING OR WITHDRAWING BURDENSOME TREATMENT IS NOT THE SAME AS ABANDONING THE PATIENT.
A decision not to escalate dialysis, ventilation, resuscitation or another life-sustaining intervention can coexist with intensive treatment of pain, breathlessness, anxiety, agitation and distress.
Comfort care is still active medicine.
The question is no longer simply whether an intervention can prolong biological life.
It is:
WHAT IS THE GOAL OF THIS INTERVENTION, AND DOES IT STILL SERVE THE PATIENT?
Culture and religion become inseparable from these decisions.
Different people understand suffering, autonomy, family responsibility, disclosure, hope and death differently. Some favour individual decision-making; others understand decisions primarily through family or community.
The psychiatrist must therefore approach cultural difference with curiosity rather than assumption:
Spirituality may also become increasingly important.
For some, approaching death intensifies faith.
For others, it produces anger, doubt or a sense of abandonment.
Psychiatry does not need to provide theological answers.
It needs to recognise when the patient’s suffering is partly existential.
Psychotherapy therefore changes as life becomes shorter.
There may no longer be time for lengthy reconstruction of personality or elaborate therapeutic programmes.
Therapy becomes concentrated around what matters now:
RELATIONSHIPS • MEANING • DIGNITY • FORGIVENESS • LEGACY • UNFINISHED BUSINESS • CONNECTION
Life review may help patients recognise the coherence and value of their lives.
Meaning-centred therapy may help preserve purpose despite approaching death.
Dignity-focused approaches can help patients communicate what they most want remembered.
Sometimes the most important intervention is simply remaining present.
The psychiatrist does not need to remove every painful emotion.
Some emotions belong to the experience of saying goodbye.
Then Holmes finds a note beside one patient’s bed:
“I wish I wouldn’t wake up tomorrow.”
This cannot be interpreted automatically.
A wish for death exists on a spectrum. It may represent transient exhaustion, uncontrolled symptoms, demoralisation, major depression, hopelessness, fear, a desire to escape suffering or a sustained request concerning hastened death.
The psychiatrist therefore asks:
WHY NOW?
What has changed?
Is the patient in pain?
Are they frightened?
Do they feel they have become a burden?
Are they depressed?
Is delirium present?
Have they lost autonomy or dignity?
Is there unfinished conflict?
What does death represent to them?
Understanding the wish may reveal suffering that can still be relieved.
Finally, Holmes notices another group standing quietly at the edge of the ward.
The clinicians.
Repeated exposure to suffering and death affects doctors, nurses and other healthcare workers too. Clinicians may experience grief, helplessness, guilt, moral distress or emotional withdrawal. During disasters and pandemics, these pressures can become particularly intense.
Good terminal care therefore requires a team capable of caring without becoming emotionally absent.
Holmes closes the final chart.
Medicine has not failed because a patient dies.
Death eventually lies beyond medicine’s power.
But suffering does not.
The final equation becomes:
SYMPTOM CONTROL + COMMUNICATION + AUTONOMY + RELATIONSHIPS + CULTURE + MEANING + DIGNITY
And the final question changes from:
“How do we stop this person from dying?”
to:
“How do we care for this person while they are dying?”
Key Takeaways
* Terminal illness changes the goals of medicine rather than ending medical care.
* The transition is better conceptualised as cure-focused care → comfort-focused care, not treatment → no treatment.
* Palliative care seeks to reduce suffering and maximise quality of remaining life.
* Terminal illness has biological, psychological, social, cultural, spiritual and existential dimensions.
* Psychiatry therefore has an important role in terminal and palliative care.
* The psychiatrist often works simultaneously with the patient, family and healthcare team.
* The central psychiatric principle is to avoid both under-recognising psychiatric illness and pathologising normal responses to dying.
* Sadness in someone who is dying is not automatically depression.
* Fear of death is not automatically an anxiety disorder.
* Psychological distress nevertheless deserves attention even when it does not constitute a formal disorder.
* Previous psychiatric illness is an important predictor of psychiatric difficulty during advanced disease.
* Serious physical illness can also produce new psychiatric syndromes.
* Medication effects must always be considered.
* The underlying medical disease may directly alter mental state.
* Pain is one of the central concerns of terminal care.
* Pain and suffering are related but not identical.
* Pain refers primarily to the unpleasant sensory and emotional experience associated with actual or potential tissue damage.
* Suffering may additionally encompass fear, loneliness, helplessness, relational conflict and existential distress.
* Psychological factors can alter the experience of pain.
* Anxiety can lower pain tolerance.
* Depression may amplify suffering.
* Effective analgesia can itself be a powerful psychiatric intervention.
* Clinicians should take patients’ reports of pain seriously.
* Fear of addiction should not result in inadequate analgesia in dying patients.
* Behavioural and psychological interventions can complement pharmacological pain treatment.
* Relaxation can increase perceived control.
* Meditation and mindfulness may help selected patients.
* Hypnosis and imagery may be useful for some.
* Psychotherapy can help distinguish physical pain from broader suffering.
* Spiritual support may be important where suffering has religious or existential dimensions.
* Fatigue is extremely common in advanced illness.
* It can profoundly impair quality of life.
* Fatigue is multidimensional.
* Physical, cognitive, affective and motivational components may coexist.
* Disease itself may produce fatigue.
* Anaemia, nutritional problems and metabolic abnormalities can contribute.
* Medication can contribute.
* Sleep disturbance can contribute.
* Depression can contribute.
* Clinicians should avoid assuming that fatigue is purely psychological.
* They should equally avoid assuming that fatigue is inevitably untreatable because the patient is medically ill.
* Physical and psychological causes commonly coexist.
* Anxiety is common in advanced disease.
* Patients may describe fear, apprehension or rumination rather than using the word anxiety.
* Anxiety may present somatically.
* Restlessness can be a manifestation.
* Tachycardia may occur.
* Gastrointestinal distress and nausea may occur.
* Insomnia may occur.
* Breathlessness may intensify anxiety.
* Tremor and numbness can occur.
* Anxiety can worsen functional impairment.
* Anxiety may interfere with medical treatment.
* It may interfere with meaningful interaction with family.
* Pre-existing anxiety disorders may worsen during terminal illness.
* Medical causes of anxiety should be considered.
* Medication adverse effects should also be considered.
* Supportive psychotherapy may help.
* Relaxation and breathing techniques may help selected patients.
* Medication may be appropriate where symptoms are severe.
* Depression is also common in advanced disease.
* Reported prevalence varies considerably according to diagnostic criteria and patient population.
* Diagnosing depression in terminal illness is challenging because somatic depressive symptoms overlap with physical disease.
* Appetite change may arise from illness.
* Weight loss may arise from illness.
* Sleep disturbance may arise from illness.
* Fatigue may arise from illness.
* Cognitive impairment may arise from illness or treatment.
* Greater emphasis may therefore need to be placed on psychological features.
* Persistent hopelessness is important.
* Worthlessness is important.
* Excessive guilt is important.
* Persistent anhedonia is important.
* Social withdrawal may provide useful diagnostic information.
* Suicidal thinking requires exploration.
* The Endicott substitution approach was developed to address the overlap between physical illness and somatic depression criteria.
* It substitutes selected psychological manifestations for ambiguous somatic symptoms.
* The purpose is to avoid missing depression merely because physical illness explains some conventional criteria.
* Depression in terminal illness remains treatable.
* Antidepressants may be appropriate when prognosis allows sufficient time for therapeutic onset.
* Medication choice should consider adverse effects and the patient’s particular symptoms.
* Sedating antidepressants may sometimes be advantageous where insomnia is prominent.
* Conversely, sedation may be undesirable when alertness and interaction with family are priorities.
* Psychostimulants may sometimes be considered when rapid improvement in energy or engagement is clinically important and life expectancy is short.
* Treatment goals should be individualised.
* In terminal care, seemingly small improvements can have enormous human significance.
* Being sufficiently alert to speak with family may be a major therapeutic outcome.
* Delirium becomes increasingly common in advanced disease.
* Its prevalence becomes particularly high near the end of life.
* Delirium may be hyperactive, hypoactive or mixed.
* Hypoactive delirium can easily be missed.
* Terminal delirium is frequently multifactorial.
* Medications can contribute.
* Opioids and other centrally acting medications may contribute in susceptible patients.
* Dehydration can contribute.
* Infection can contribute.
* Electrolyte disturbance can contribute.
* Hypoxia can contribute.
* Metabolic encephalopathy can contribute.
* Organ failure can contribute.
* The underlying disease can contribute.
* Some episodes of delirium remain reversible even in advanced illness.
* Medication-related and dehydration-related delirium may be particularly amenable to reversal.
* The extent of investigation should reflect the patient’s goals of care.
* Diagnostic investigation is not automatically inappropriate simply because a patient is dying.
* Conversely, invasive investigation is not automatically appropriate simply because a cause might theoretically be identified.
* Ask whether identifying the cause would produce a meaningful and tolerable intervention.
* Comfort becomes an increasingly important determinant of investigation.
* Orientation cues such as clocks and calendars may help.
* Avoiding unnecessary changes of room or staff can reduce disorientation.
* Protecting the sleep–wake cycle is useful.
* Hydration and electrolyte correction may be appropriate where consistent with treatment goals.
* Severe agitation may require pharmacological management.
* Terminal illness affects families as well as patients.
* Family members often experience anticipatory grief.
* Caregiving can produce exhaustion.
* Families may experience guilt.
* Old family conflicts may re-emerge.
* Relatives may disagree about prognosis or treatment.
* They may differ in how much medical intervention they believe should continue.
* Good communication is therefore central to terminal care.
* Family meetings can clarify goals and reduce conflict.
* Decision-making becomes particularly complex when patients lose capacity.
* Advance care planning can preserve autonomy after capacity is lost.
* Advance directives may provide guidance.
* A nominated healthcare proxy can assist decision-making.
* Surrogate decision-makers ideally attempt to represent the patient’s preferences rather than their own.
* Family members do not always accurately predict what patients would have chosen.
* Surrogate decision-making can impose substantial psychological burden.
* Surrogates may experience uncertainty and guilt after the patient’s death.
* Clinicians should therefore support surrogate decision-makers rather than simply transfer responsibility to them.
* When known, previously expressed patient wishes should guide care.
* Where wishes are unknown, decisions commonly focus on the patient’s interests and values.
* Withholding treatment and withdrawing treatment are ethically distinct in people’s intuitions but may serve the same clinical goal when an intervention no longer benefits the patient.
* Withdrawal of burdensome treatment does not mean withdrawal of care.
* Comfort treatment should continue.
* Decisions may involve resuscitation.
* They may involve ventilation.
* They may involve dialysis.
* They may involve artificial nutrition or hydration.
* They may involve antibiotics or other disease-directed interventions.
* Each decision should be considered in relation to goals, likely benefit and burden.
* Can this treatment be given? is different from Should this treatment be given to this patient now?
* Cardiopulmonary resuscitation is a medical intervention rather than a default symbol of caring.
* Decisions about CPR should reflect prognosis, goals and the likely consequences of resuscitation.
* Good palliative care should not be confused with intentionally causing death.
* Adequate symptom relief remains a central medical obligation.
* Requests or wishes concerning death require careful assessment.
* A passive statement such as “I would be happy not to wake up” does not necessarily mean the same thing as active suicidal intent.
* Desire for death exists on a spectrum.
* Some wishes are transient and diminish when symptoms or circumstances improve.
* Major depression can produce persistent suicidal thinking.
* Hopelessness is particularly important.
* Uncontrolled physical symptoms may contribute to a wish for death.
* Fear may contribute.
* Perceived dependency may contribute.
* Feeling like a burden may contribute.
* Loss of dignity may contribute.
* Existential suffering may contribute.
* Anger may sometimes be present.
* A request relating to hastened death therefore requires exploration of its meaning and context.
* The psychiatrist should ask “Why now?”
* Treatable contributors should be identified.
* Pain should be optimally managed.
* Depression should be assessed.
* Delirium should be excluded.
* Anxiety should be treated where appropriate.
* Social and relational problems should be explored.
* Spiritual or existential suffering should not be ignored.
* Capacity is important when patients make major treatment decisions.
* Capacity is decision-specific.
* A terminal diagnosis does not itself remove decision-making capacity.
* Depression does not automatically remove capacity.
* Delirium, however, commonly threatens capacity.
* Capacity may fluctuate.
* Cultural factors profoundly influence experiences of dying.
* Culture shapes concepts of illness.
* It shapes family responsibility.
* It influences communication preferences.
* It may influence attitudes towards disclosure.
* It influences decision-making styles.
* Religion may shape beliefs about suffering and death.
* Clinicians should avoid assuming that every member of a cultural or religious group holds identical beliefs.
* The patient’s own interpretation is what matters.
* A useful cultural framework considers attitudes, beliefs, context, decisions and environment.
* Trust is particularly important across cultural differences.
* Historical or contemporary healthcare inequalities may contribute to mistrust.
* Respectful curiosity is preferable to stereotyping.
* Spiritual concerns may intensify near death.
* Some patients find comfort in religious belief.
* Others experience spiritual doubt, anger or abandonment.
* Spiritual distress can contribute significantly to suffering.
* Chaplaincy or trusted religious support may therefore be valuable where desired.
* Psychotherapy remains possible in terminal illness.
* Its goals often change as time becomes shorter.
* Supportive psychotherapy can reduce isolation.
* Crisis intervention may be useful.
* Family-focused therapy can address communication and grief.
* Group supportive therapy may benefit selected patients.
* Meaning-centred psychotherapy can address existential concerns.
* Dignity-focused approaches may help patients preserve identity and legacy.
* Life review can help patients integrate the meaning of their lives.
* Therapy can facilitate unfinished conversations.
* Patients may wish to address unresolved relationships.
* They may wish to leave messages or legacies.
* Relaxation and imagery may provide moments of relief.
* Mindfulness may be useful for selected patients.
* Music therapy may also provide comfort.
* The intensity and complexity of psychotherapy should reflect the patient’s energy and cognitive capacity.
* A profoundly ill patient may not tolerate demanding cognitive therapy.
* Sometimes presence itself is therapeutic.
* The clinician should not feel compelled to fill every silence.
* Psychiatry cannot remove mortality.
* It can reduce unnecessary suffering surrounding mortality.
* Hope need not disappear when cure disappears.
* The object of hope can change.
* Hope may shift from cure to comfort.
* It may shift towards time with family.
* It may become hope for reconciliation.
* It may become hope for dignity.
* It may become hope for a peaceful death.
* Realistic hope therefore need not involve false reassurance.
* Healthcare workers themselves are psychologically affected by repeated exposure to dying.
* Clinicians may experience grief.
* They may experience helplessness.
* They may experience guilt or moral distress.
* Emotional distancing can become a defence against repeated suffering.
* Some emotional protection is necessary, but excessive detachment may impair genuine therapeutic presence.
* Teams need opportunities for support and reflection.
* Epidemics and pandemics can magnify these pressures dramatically.
* Healthcare workers may simultaneously fear for patients, colleagues, themselves and their families.
* Institutions therefore have responsibilities towards staff wellbeing as well as patient care.
* Death is not necessarily evidence that medicine has failed.
* Some diseases ultimately become irreversible despite excellent treatment.
* At that point, continuing increasingly burdensome intervention can conflict with the patient’s goals.
* Palliative medicine represents active treatment of suffering.
* Psychiatry contributes by treating symptoms, clarifying decisions, improving communication and preserving personhood.
* The fundamental system is:
BODY ↔ MIND ↔ FAMILY ↔ CULTURE ↔ MEDICAL TEAM ↔ MEANING
* The central question at the end of life is therefore not merely:
“What else can medicine do?”
* It is:
“What matters most to this person now, and how can medicine help them achieve it?”
* The final principle is:
WHEN CURE IS NO LONGER POSSIBLE, CARE REMAINS POSSIBLE.
This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit drmanaankarray.substack.com/subscribe
PSYCH 149: Psycho-Oncology
Saison 13 · Épisode 149
dimanche 11 octobre 2026 • Durée 59:13
and the end of life.
Medlock Holmes enters The House of Cancer, expecting to investigate a disease of abnormal cells.
But he quickly discovers that cancer never occupies only one room.
In the laboratory, cells divide uncontrollably. In the adjoining rooms, entirely different processes are unfolding: a newly diagnosed patient sits stunned after hearing the word cancer; another cannot sleep before a surveillance scan; another is depressed during chemotherapy; a survivor is terrified that every new pain means recurrence; a parent tries to explain illness to a child; and, in the final room, a patient with advanced disease asks not simply how long they have left, but what their remaining life means.
Holmes realises that oncology treats the tumour, but psycho-oncology examines the human being who has the tumour.
Psycho-oncology sits at the intersection of oncology, psychiatry, psychology, palliative care and the wider multidisciplinary team. Its concern stretches across the entire cancer trajectory:
PREVENTION → DIAGNOSIS → TREATMENT → REMISSION → SURVIVORSHIP → RECURRENCE → ADVANCED DISEASE → END OF LIFE
At every stage, the psychological task changes.
A diagnosis may produce shock, disbelief, fear and uncertainty. Treatment introduces pain, fatigue, nausea, altered appearance, sexual difficulties and loss of independence. Remission may bring relief but also fear of recurrence. Advanced disease raises questions of mortality, meaning, dignity and hope.
Importantly, distress is not synonymous with psychiatric disorder.
Fear after a cancer diagnosis may be entirely understandable. Sadness in someone confronting loss does not automatically constitute major depression. The psychiatrist must therefore distinguish an adaptive human response from adjustment disorder, anxiety disorder, major depression, delirium or another psychiatric syndrome.
This becomes particularly difficult because cancer and its treatment can reproduce many of the somatic symptoms ordinarily used to diagnose depression:
This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit
PSYCH 148: Endocrine and Metabolic Disorders
Saison 13 · Épisode 148
samedi 10 octobre 2026 • Durée 01:06:17
meaning disturbances of thyroid, adrenal, metabolic and reproductive systems can present as depression, anxiety, mania, psychosis or cognitive change.
Episode Description
Medlock Holmes enters The Hormonal Control Room, a vast Neo-Victorian laboratory where the brain and body communicate through an intricate network of chemical messengers.
At its centre stands the hypothalamus, connected to the pituitary gland, the master relay station. From there, illuminated pathways extend towards the:
THYROID • ADRENALS • GONADS • PANCREAS
Every pathway contains a feedback loop.
Hormones travel outward, change the activity of distant organs and the brain, and then signal backwards to regulate their own production.
Holmes quickly discovers the central rule:
HORMONES ↔ BRAIN ↔ BEHAVIOUR
Endocrine disorders can produce psychiatric symptoms early in their course, sometimes before their physical manifestations become obvious. They should therefore remain part of the differential diagnosis when depression, anxiety, cognitive impairment or other psychiatric symptoms are unusual or resistant to treatment.
The first chamber controls the thyroid.
When thyroid activity falls, the entire room appears to slow.
The patient becomes tired. Thought becomes sluggish. Memory and concentration deteriorate. Motivation falls. Mood darkens.
The resemblance to primary depression is striking.
This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit
PSYCH 147: Diabetes - Psychosocial Issues and Psychiatric Disorders
Saison 13 · Épisode 147
vendredi 9 octobre 2026 • Durée 53:44
making mental health inseparable from metabolic health.
Episode Description
Medlock Holmes enters The Metabolic Control Room, an immense Neo-Victorian chamber built around a glowing bloodstream. At its centre sits a vast brass dial labelled GLUCOSE, connected to the pancreas, brain, heart, kidneys, eyes and peripheral nerves.
At first, the machinery seems straightforward.
In type 1 diabetes, autoimmune destruction of pancreatic β cells leaves the body producing little or no insulin.
In type 2 diabetes, insulin resistance dominates initially, often followed over time by declining insulin production.
But Holmes soon discovers that controlling diabetes requires something no machine can supply automatically: continuous human self-management. The chapter describes diabetes as an unusually complex chronic illness in which successful outcomes depend heavily on the patient’s own behaviour and supportive relationships.
Then Holmes notices another mechanism connected directly to the glucose dial.
It is labelled:
DEPRESSION
When depression enters the system, energy falls. Motivation weakens. Concentration becomes harder. Exercise decreases. Diet may deteriorate. Prescriptions are missed. Appointments become harder to attend. Diabetes begins to feel impossible to control.
Worsening diabetes then creates more symptoms, complications, restrictions and distress.
The machine forms a loop:
This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit
PSYCH 146: Respiratory Disorders
Saison 13 · Épisode 146
jeudi 8 octobre 2026 • Durée 59:58
and psychiatric treatment.
Episode Description
Medlock Holmes enters The Chamber of Breath, an immense Neo-Victorian respiratory laboratory where a pair of mechanical lungs expands and contracts beneath an intricate network connecting the lungs, brain, emotions and behaviour.
At first, the mystery appears entirely pulmonary. Asthma narrows reactive airways. COPD progressively restricts airflow. Interstitial lung disease scars the tissue surrounding the alveoli. Cystic fibrosis fills the respiratory system with the consequences of abnormal CFTR function. Respiratory failure produces hypoxia and hypercapnia.
But Holmes quickly discovers that breathing is unlike almost any other bodily function.
And this makes respiratory illness particularly important to psychiatry.
Dyspnoea can generate fear. Fear can alter breathing. Hyperventilation can create dizziness, chest tightness, paraesthesia and further breathlessness. Those sensations can then be interpreted catastrophically:
“I CAN’T BREATHE.”
The alarm intensifies.
Breathing accelerates.
Carbon dioxide falls.
Physical sensations increase.
Fear escalates again.
Holmes finds himself confronting one of respiratory psychiatry’s central diagnostic problems:
LUNG DISEASE → DYSPNOEA → FEAR
or
FEAR → HYPERVENTILATION → DYSPNOEA
or, very commonly:
This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit
PSYCH 145: Obesity
Saison 13 · Épisode 145
mercredi 7 octobre 2026 • Durée 01:10:10
the development and management of obesity.
Medlock Holmes enters The Great Energy Exchange, an immense Neo-Victorian metabolic laboratory where every calorie entering the body passes through a bewildering network of biological, psychological and environmental machinery.
At first, the equation appears almost embarrassingly simple:
ENERGY IN > ENERGY OUT → WEIGHT GAIN
But Holmes quickly discovers that the equation describes what happens, not why it happens.
Behind the balance are hundreds of interconnected mechanisms: genetic susceptibility, appetite hormones, adipose tissue, metabolism, the gut microbiome, reward circuitry, mood, stress, sleep, learned behaviour, medications, food availability and the environment itself. Obesity is therefore not simply a failure of willpower; it is a complex condition emerging from the interaction between biology and the world in which a person lives.
The investigation begins with measurement. Body mass index, calculated as weight in kilograms divided by height in metres squared, remains the most widely used clinical measure. A BMI of 25–29.9 falls within the overweight range, 30 or above within obesity, and above 40 within severe obesity. Yet Holmes notices immediately that BMI is an imperfect instrument: it cannot distinguish muscle from fat or account adequately for fitness, bone density and other dimensions of metabolic health.
More important is what obesity does across the body. The medical map on the wall connects it with hypertension, dyslipidaemia, type 2 diabetes, cardiovascular disease, obstructive sleep apnoea, osteoarthritis, fatty liver disease, reflux, reproductive difficulties and several cancers. Depression and anxiety appear on the same map.
But Holmes refuses to draw a one-way arrow from obesity to mental illness.
Instead:
OBESITY ↔ DEPRESSION
OBESITY ↔ ANXIETY
This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit
PSYCH 144: Gastrointestinal Disorders
Saison 13 · Épisode 144
mardi 6 octobre 2026 • Durée 43:52
and the extraordinary bidirectional conversation of the brain–gut–microbiome axis.
Medlock Holmes enters The Great Gut–Brain Exchange, an immense Neo-Victorian communication network in which the brain and gastrointestinal tract are joined by constantly moving signals. Messages travel downward through the autonomic nervous system, HPA axis and neuroendocrine pathways, while sensory, immune, hormonal and microbial signals travel back towards the brain.
There is no single direction of causation.
Instead:
BRAIN ↔ GUT ↔ IMMUNE SYSTEM ↔ MICROBIOME
This brain–gut–microbiome axis provides the central framework for understanding why gastrointestinal illness and psychiatric symptoms so frequently coexist. Biological, psychological and social influences are not competing explanations; they are interacting parts of the same system.
Holmes first investigates inflammatory bowel disease, principally Crohn disease and ulcerative colitis. These are inflammatory diseases, yet their consequences extend far beyond the bowel. Depression and anxiety are common, particularly when disease is active, while pain, fatigue, cognitive difficulties, insomnia, fear of incontinence and the experience of repeated hospitalisation or surgery can profoundly affect psychological wellbeing. The relationship may also operate in the opposite direction, with psychological distress influencing symptom experience, self-management and potentially disease outcomes.
Treatment itself can create psychiatric complications. One chamber contains a particularly important clue: corticosteroids. A patient being treated successfully for severe inflammatory bowel disease may develop agitation, confusion, suspiciousness or psychosis. The psychiatrist must therefore investigate not merely the disease but also what has been done to treat it.
Holmes then enters the much larger and more complicated territory of functional gastrointestinal disorders, now commonly conceptualised as disorders of gut–brain interaction. Here, symptoms are genuine even when conventional structural investigations are normal.
This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit
PSYCH 143: Cardiovascular Disorders
Saison 13 · Épisode 143
lundi 5 octobre 2026 • Durée 57:08
Medlock Holmes enters The Engine Room of the Heart, where an enormous mechanical heart is connected to the brain by networks carrying stress, emotion, behaviour, autonomic signals and medication effects.
The relationship is strikingly bidirectional. Cardiovascular disease can produce anxiety, depression, cognitive disturbance and trauma-related symptoms, while psychiatric disorders and psychological stress can influence cardiovascular risk, recovery and mortality. Behaviour provides another bridge: smoking, inactivity, poor diet and reduced adherence can all become more prominent during psychiatric illness. Cardiovascular disease remains a major cause of death and disability, making these interactions clinically important.
Holmes begins with coronary artery disease (CAD). Depression is strongly associated with both the development and progression of CAD, with behavioural pathways such as smoking, inactivity and poor adherence interacting with possible biological pathways involving autonomic function, the HPA axis, endothelial function and platelet activation. Anxiety, PTSD, chronic stress and low social support also enter the investigation.
The relationship becomes especially important in severe mental illness. People with schizophrenia, schizoaffective disorder and bipolar disorder experience substantial cardiovascular morbidity through overlapping influences: smoking, sedentary behaviour, reduced access to healthcare, metabolic illness and the cardiometabolic effects of some psychotropic medications.
Holmes then enters the chambers of heart failure, transplantation and ventricular assist devices, where psychiatric assessment becomes part of complex cardiovascular treatment. Depression, anxiety, cognition, substance use, adherence, social support and decision-making capacity may all influence care.
But another mystery emerges: sometimes the heart masquerades as the mind. Arrhythmias, syncope and pulmonary thromboembolism can resemble panic or functional symptoms. Conversely, panic disorder, anxiety and somatic symptom disorder can produce chest pain and palpitations that resemble cardiac disease.
The ECG therefore becomes part of the psychiatrist’s toolkit. Psychotropic medications can affect heart rate, conduction, blood pressure and ventricular repolarisation. Holmes pays particular attention to , recognising that risk depends not simply on one medication but on the combination of drug, dose, cardiac disease, age, sex, renal or hepatic dysfunction, electrolyte abnormalities, bradycardia and interacting medications.
This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit
PSYCH 142: Consultation-Liaison Psychiatry and Psychosomatic Medicine
Saison 13 · Épisode 142
dimanche 4 octobre 2026 • Durée 54:29
Medlock Holmes enters The Hospital of Two Wings.
For generations, one wing has been labelled BODY and the other MIND. Patients are routinely carried from one to the other, as though every symptom must belong exclusively to one side.
Holmes immediately notices the flaw.
A bridge connects them.
Consultation-liaison psychiatry operates on this bridge: the part of psychiatry concerned with psychiatric problems arising within medical settings and with the complex, bidirectional relationships between physical illness and mental health. The older term psychosomatic medicine literally reflects the relationship between psyche and soma - mind and body - but historically became burdened by the misleading implication that symptoms were somehow imaginary or “all in the head”. The field increasingly adopted the name consultation-liaison psychiatry to better describe its clinical work.
The history of the specialty becomes a detective story in its own right. Holmes follows medicine from ancient recognition that emotions influence the body, through hysteria and conversion, psychoanalytic theories, physiological models of stress, psychoneuroimmunology and finally the modern biopsychosocial model.
The crucial insight is that causation rarely travels in only one direction:
Modern C-L psychiatry therefore addresses an enormous range of problems: delirium and dementia caused by medical disease; depression and anxiety occurring alongside physical illness; psychiatric effects of medications such as corticosteroids; somatic symptom disorders; substance withdrawal; psychiatric complications of psychotropic treatment; adjustment to cancer, transplantation, disability or terminal illness; suicidality; treatment adherence; and assessment of decision-making capacity.
Holmes also discovers why this matters beyond psychological wellbeing. Psychiatric morbidity is exceptionally common among medically ill patients and can affect treatment adherence, disability, length of hospitalisation, quality of life and medical outcomes. The chapter reports psychiatric morbidity in roughly of patients with medical conditions, depending on the illness, with delirium occurring in approximately .
This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit
PSYCH 141: Personality Disorders
Saison 13 · Épisode 141
samedi 3 octobre 2026 • Durée 45:53
Personality disorder emerges not because someone has a distinctive personality, but when enduring patterns become sufficiently inflexible and maladaptive to repeatedly disrupt the self, relationships and functioning.
Medlock Holmes enters The House of Personality, an extraordinary mansion that has been under construction since childhood.
Its foundations contain inherited temperament. Its rooms have been shaped by development and experience. Its doors determine how readily someone approaches or avoids the world; its windows influence how they interpret other people; and its internal corridors represent the habitual ways in which emotion, identity, relationships and behaviour become connected.
Every house is different.
Difference itself is not disorder.
The mystery begins when Holmes discovers that some houses have become rigid. The same doors open regardless of circumstance. The same corridors are travelled despite repeatedly leading to conflict. Strategies that may once have been adaptive become increasingly difficult to modify.
This chapter takes Holmes beneath diagnostic labels to explore the architecture of personality itself. Personality is presented as a dynamic biopsychosocial system emerging from interactions between temperament, character, learning, development, environment and self-awareness.
Holmes encounters two competing maps of personality disorder. The traditional DSM model divides disorders into three familiar clusters: Cluster A, characterised broadly by odd or eccentric patterns; Cluster B, by dramatic, emotional or impulsive patterns; and Cluster C, by anxious or fearful patterns. Yet the boundaries overlap considerably.
A newer dimensional perspective asks a different question. Rather than simply asking “Which personality disorder does this person have?”, clinicians can ask:
“How impaired is personality functioning, and what traits characterise that impairment?”
This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit
He examines persistent low mood, anhedonia, hopelessness, guilt, worthlessness, withdrawal, suicidal thinking and the patient’s psychological relationship with their illness.
Anxiety is equally complex. Patients may fear treatment, procedures, pain, disfigurement, disability, recurrence or death. Some develop panic symptoms. Others experience anticipatory nausea or intense anxiety associated with chemotherapy. Cancer can also be experienced as traumatic, although fear and intrusive memories do not automatically mean PTSD.
Then Holmes encounters one of psycho-oncology’s most important diagnostic traps: delirium.
In a patient with cancer, sudden confusion or behavioural change demands a medical investigation. Infection, metabolic disturbance, organ failure, brain involvement, medications, opioids, corticosteroids and other treatment-related factors may all contribute.
The rule is simple:
A NEW PSYCHIATRIC PRESENTATION IN CANCER MAY HAVE A MEDICAL CAUSE UNTIL PROVEN OTHERWISE.
Cancer treatments themselves can affect mental state. Corticosteroids may produce insomnia, mood disturbance, mania, psychosis or delirium. Other medications can interact with psychotropics, and organ impairment can alter drug metabolism. Psycho-oncology therefore requires genuine consultation-liaison thinking: psychiatric treatment cannot be separated from the oncology treatment plan.
But Holmes finds another chart on the wall labelled DISTRESS.
Distress exists on a continuum. At one end are understandable vulnerability, sadness and fear. Further along are disabling anxiety, depression, social disruption, spiritual crisis and psychiatric illness.
This is why psychosocial distress should be recognised rather than waiting for patients to volunteer it.
Yet the investigation cannot stop with the patient.
Cancer enters relationships.
Partners may become carers. Children may become frightened. Sexual relationships may change. Employment and finances may deteriorate. Roles within families may reverse. Carers themselves can develop substantial psychological distress.
The true unit of care may therefore become:
PATIENT ↔ FAMILY ↔ CLINICAL TEAM
Body image and sexuality form another major part of the case. Surgery, hair loss, weight change, scars, stomas, mastectomy, altered fertility and treatment-related sexual dysfunction may change how people experience their bodies and identities. These issues should not be dismissed as secondary simply because survival is the immediate medical priority.
Then Holmes reaches The Survivorship Wing.
The patient has finished treatment.
Everyone expects life to return to normal.
But the patient no longer knows what normal means.
Survivors may experience persistent fatigue, cognitive complaints, sexual difficulties, altered relationships, occupational disruption and fear of recurrence. Follow-up appointments and surveillance scans can themselves become recurring psychological stressors.
Survival therefore does not necessarily mean the psychological story has ended.
In advanced cancer, the questions change again.
The aim is not simply to eliminate distress. Some distress is inseparable from confronting mortality. The task becomes helping patients retain connection, dignity, purpose and meaning while treating remediable depression, anxiety, delirium and suffering.
This distinction becomes crucial when a patient expresses a wish to die.
Such statements require careful exploration rather than immediate assumptions. They may represent uncontrolled symptoms, depression, hopelessness, fear of dependency, demoralisation, loss of dignity, existential suffering or a sustained desire for hastened death.
The psychiatrist asks:
What does the wish mean?
The answer may reveal something treatable.
Psychotherapy therefore occupies a central place in psycho-oncology. Supportive therapy, cognitive-behavioural approaches, group interventions, family work and existential or meaning-centred approaches can help patients manage fear, uncertainty, loss and mortality.
Psychopharmacology can also be important, but treatment must account for physical illness, drug interactions, organ function, prognosis, adverse effects and the patient’s goals of care.
For children with cancer, Holmes finds another principle written above the paediatric ward:
CHILDREN OFTEN KNOW MORE THAN ADULTS THINK THEY KNOW.
Repeated hospital visits, procedures, chemotherapy, hair loss and conversations around them make secrecy difficult. Communication should therefore be truthful while remaining developmentally appropriate. Avoidance intended to protect the child can sometimes increase anxiety, while age-appropriate explanation can reduce uncertainty.
The psychiatrist also cares indirectly for parents and siblings, because childhood cancer affects the entire family system.
Finally, Holmes notices that the clinical staff themselves are represented on the hospital map.
Cancer clinicians repeatedly encounter suffering, uncertainty, deterioration and death. Psycho-oncology therefore extends beyond the patient to communication within teams, professional boundaries, grief and the emotional burden carried by healthcare workers.
Holmes closes the casebook.
The fundamental mistake was believing that cancer could be understood only by studying the tumour.
The complete equation is larger:
CANCER ↔ BODY ↔ BRAIN ↔ EMOTION ↔ IDENTITY ↔ RELATIONSHIPS ↔ MEANING
And the central principle of psycho-oncology becomes:
Treat the cancer - but care for the person living through it.
Key Takeaways
* Psycho-oncology is the psychiatric and psychological study and treatment of people affected by cancer.
* It forms an important part of consultation-liaison psychiatry.
* Its scope extends from cancer prevention and diagnosis through treatment, survivorship, recurrence, advanced disease and end-of-life care.
* Psycho-oncology is inherently multidisciplinary.
* Oncology, psychiatry, psychology, nursing, social work, palliative care and spiritual care may all contribute.
* Cancer affects psychological health as well as physical health.
* Psychological and behavioural factors can also influence cancer prevention, detection, treatment engagement and adaptation.
* The psychological meaning of cancer varies enormously between individuals.
* A person’s response depends partly upon cancer type, stage, prognosis and treatment.
* It also depends upon personality, previous psychiatric history, coping style, relationships, culture, socioeconomic circumstances and previous experiences of illness.
* There is therefore no single psychological response to cancer.
* Cancer commonly produces distress.
* Distress exists on a continuum rather than representing a single diagnosis.
* Mild distress may represent an understandable response to illness.
* Severe distress can substantially impair functioning and quality of life.
* Distress does not automatically indicate psychiatric disorder.
* Conversely, understandable distress should not prevent clinicians recognising treatable psychiatric illness.
* Screening for psychological distress has become an important component of comprehensive cancer care.
* The psychological impact of cancer changes across the illness trajectory.
* Diagnosis commonly produces shock, fear, disbelief and uncertainty.
* Patients may initially experience difficulty processing complex information.
* Emotional responses can change considerably once treatment begins.
while simultaneously recognising that every arrow can operate in both directions.
* The central clinical question is not simply:
“Does this patient have a psychiatric disorder?”
* It is:
“How is this person experiencing cancer, what is causing suffering, what is adaptive, what has become pathological, and what can we meaningfully change?”
* The central principle of psycho-oncology is therefore:
TREAT THE DISEASE • RELIEVE THE SYMPTOMS • RECOGNISE THE DISTRESS • PRESERVE THE PERSON
A patient who appears to have panic disorder, severe anxiety or occasionally a manic-like state may therefore require a thyroid investigation rather than simply another psychiatric prescription.
Holmes moves deeper into the laboratory and reaches the adrenal system.
Here the hypothalamus releases CRH, the pituitary releases ACTH, and the adrenal cortex releases CORTISOL.
CRH → ACTH → CORTISOL
Normally cortisol follows a circadian rhythm and participates in the body’s response to stress.
But when cortisol remains excessively high, Holmes enters the chamber of Cushing syndrome.
The excess cortisol does not always originate from disease.
Sometimes it comes from treatment.
A bottle labelled CORTICOSTEROIDS feeds directly into the chamber.
As the dose rises, the psychiatric risk rises with it.
This produces another essential clinical rule:
MEDICATION CAN BECOME THE ENDOCRINE DISORDER
A patient who develops sudden insomnia, increased energy, irritability, pressured speech or psychosis after starting high-dose corticosteroids may not have spontaneously developed primary bipolar disorder.
The timeline is the clue.
Next Holmes enters a chamber where cortisol has almost disappeared.
This is adrenal insufficiency.
The patient becomes weak, exhausted, apathetic and depressed.
Again, the psychiatric resemblance is deceptive.
But Holmes finds physical clues:
WEIGHT LOSS • HYPOTENSION • HYPOGLYCAEMIA • HYPONATRAEMIA • HYPERKALAEMIA
The lesson repeats:
WHEN PSYCHIATRIC SYMPTOMS AND SYSTEMIC PHYSICAL SIGNS TRAVEL TOGETHER, LOOK FOR THE COMMON MECHANISM.
Holmes continues to the metabolic chamber.
Here insulin determines how effectively glucose can enter and be used by tissues.
Type 1 diabetes reflects autoimmune destruction of pancreatic β cells.
Type 2 diabetes is dominated by insulin resistance and progressive metabolic dysfunction.
But Holmes discovers that insulin resistance is not merely a peripheral metabolic phenomenon.
It has increasingly been associated with:
MOOD • COGNITION • DEPRESSION
The relationship appears bidirectional.
INSULIN RESISTANCE ↔ DEPRESSION
Lifestyle, inflammation, genetics, medication and metabolic signalling may all contribute.
And once again psychiatry can alter the system it is attempting to treat.
Some second-generation antipsychotics substantially increase metabolic risk, particularly:
CLOZAPINE • OLANZAPINE
Holmes therefore places five gauges beside every antipsychotic prescription:
WEIGHT • BLOOD PRESSURE • GLUCOSE • LIPIDS • FAMILY HISTORY
The next chamber belongs to polycystic ovary syndrome.
Holmes sees not a simple ovarian disease but a self-perpetuating endocrine network involving:
LH/FSH DYSREGULATION
↓
HYPERANDROGENISM
↔
INSULIN RESISTANCE
↔
OBESITY
↔
OVULATORY DYSFUNCTION
The diagram in the source chapter illustrates precisely this kind of circular system: pituitary dysfunction, impaired follicular development, hyperandrogenism, insulin resistance, obesity and peripheral hormone metabolism can reinforce one another rather than forming a simple one-directional pathway.
Depression and anxiety are more common in women with PCOS, although the reasons remain complex.
Then Holmes notices another psychiatric connection:
VALPROATE ↔ PCOS RISK
Once again, the distinction between psychiatry and endocrinology disappears.
Finally Holmes reaches the prolactin chamber.
Unlike most pituitary hormones, prolactin is normally held under restraint by:
DOPAMINE
Block dopamine D2 receptors, and prolactin can rise.
The mechanism suddenly explains a familiar psychiatric adverse effect:
Risperidone is particularly important among atypical antipsychotics, while switching to a prolactin-sparing medication such as aripiprazole may reduce prolactin in appropriate circumstances.
Holmes finally understands the architecture of the entire laboratory.
Psychiatry does not simply sit beside endocrinology.
The two systems continuously intersect.
A psychiatric disorder can alter endocrine physiology.
An endocrine disorder can create psychiatric symptoms.
A psychiatric medication can produce endocrine disease.
And an endocrine treatment can alter mental state.
40. Iatrogenic Corticosteroid Exposure Is Especially Important
In ordinary clinical practice, corticosteroid treatment is a major cause of hypercortisolism.
Psychiatric Effects of Cortisol Excess
41. Depression Is Common in Cushing Syndrome
But the neuropsychiatric presentation is broader than depression.
42. Irritability and Emotional Lability Are Particularly Important
The patient may become:
* emotionally reactive
* irritable
* anxious
* socially withdrawn.
43. Sleep Disturbance Is Common
Including reduced sleep efficiency and early-morning awakening.
44. Psychosis and Mania Can Occur
They are less common than depressive symptoms in endogenous Cushing syndrome but become particularly relevant with high-dose corticosteroid exposure.
Steroid-Induced Psychiatric Syndromes
45. Always Ask About Corticosteroids in a New Manic or Psychotic Presentation
Particularly:
* prednisone
* dexamethasone
* other systemic glucocorticoids.
46. Steroid Psychiatric Toxicity Is Dose Related
The chapter describes a substantial rise in psychiatric adverse effects at higher prednisone doses.
47. Symptoms Often Begin Quickly
Steroid-related psychiatric disturbance can emerge:
WITHIN DAYS TO WEEKS
This temporal relationship is diagnostically valuable.
48. Steroid-Induced Activation Can Look Very Much Like Mania
Look for:
REDUCED SLEEP
INCREASED ENERGY
PRESSURED SPEECH
INCREASED ACTIVITY
IRRITABILITY
ANXIETY
and sometimes:
PSYCHOSIS
Cortisol and Cognition
49. Chronic Hypercortisolism Can Impair Cognition
Common difficulties include:
* concentration
* declarative memory
* verbal memory
* working memory
* attention
* executive functioning.
50. The Hippocampus Is Particularly Important
Prolonged glucocorticoid exposure has been associated with reduced hippocampal volume and impaired memory.
A useful connection is:
CORTISOL → HIPPOCAMPUS → MEMORY
51. Cognitive Impairment Is Not Simply Secondary to Depression
The chapter notes that cognitive deficits can correlate with cortisol/ACTH without correlating with depression severity.
So:
MOOD EFFECTS ≠ COGNITIVE EFFECTS
They may arise partly through different mechanisms.
Steroid Withdrawal
52. Withdrawal Can Also Produce Psychiatric Symptoms
Possible symptoms include:
* depression
* emotional lability
* weakness
* memory impairment
* delirium.
53. Abrupt Withdrawal Can Be Medically Dangerous
Rapid corticosteroid cessation can precipitate:
ADRENAL CRISIS
Long-term systemic steroids generally require appropriate tapering rather than casual abrupt cessation.
Adrenal Insufficiency
54. Adrenal Insufficiency Means Inadequate Adrenal Steroid Production
It may be:
* primary - adrenal disease
* secondary - deficient pituitary ACTH
* tertiary - deficient hypothalamic CRH.
55. Primary Adrenal Insufficiency Is Addison Disease
Autoimmune destruction is the major cause described in the chapter.
56. Secondary/Tertiary Disease Is Especially Relevant After Steroid Exposure
Exogenous corticosteroids suppress the HPA axis.
Abrupt withdrawal can therefore expose the body’s inability to immediately resume adequate endogenous cortisol production.
57. Chronic Adrenal Insufficiency Can Resemble Depression
Think:
FATIGUE
APATHY
LOW MOOD
IRRITABILITY
ANXIETY
WEIGHT LOSS
LOSS OF LIBIDO
58. Physical Clues Help
Particularly:
HYPOTENSION
HYPONATRAEMIA
HYPERKALAEMIA
HYPOGLYCAEMIA
and, in primary disease:
HYPERPIGMENTATION
59. Acute Adrenal Insufficiency Is a Medical Emergency
Altered mental state, delirium or even psychotic symptoms can occur alongside severe physiological disturbance.
Diabetes and Insulin Resistance
60. Diabetes Is Defined by Hyperglycaemia With Absolute or Relative Insulin Deficiency
The chapter distinguishes:
TYPE 1 → AUTOIMMUNE β-CELL DESTRUCTION
from
TYPE 2 → INSULIN RESISTANCE + PROGRESSIVE β-CELL DYSFUNCTION
61. Type 2 Diabetes Usually Develops Gradually
Insulin resistance can initially be compensated by increased insulin production.
Eventually pancreatic compensation becomes inadequate:
INSULIN RESISTANCE
↓COMPENSATORY HYPERINSULINAEMIA↓β-CELL FAILURE↓
HYPERGLYCAEMIA
62. Classic Diabetes Symptoms Are Easy to Remember as the “Three Ps”
POLYURIA
POLYDIPSIA
POLYPHAGIA
Other features include fatigue, blurred vision, poor wound healing and recurrent infection.
Diabetes and Psychiatry
63. Depression and Type 2 Diabetes Have a Bidirectional Relationship
DEPRESSION ↔ TYPE 2 DIABETES
Neither direction alone adequately explains the association.
64. Insulin Resistance May Be Part of the Connection
Insulin resistance is increasingly being investigated as a potential contributor to:
* depression
* mood instability
* cognitive dysfunction.
65. Inflammation May Provide Another Bridge
Insulin resistance is associated with a pro-inflammatory state.
Inflammatory mechanisms have also been implicated in some depressive illness.
66. Lifestyle Risk Factors Are Shared
Including:
* physical inactivity
* diet
* obesity
* smoking.
Antipsychotics and Diabetes
67. Psychiatric Treatment Can Increase Diabetes Risk
Second-generation antipsychotics differ in their metabolic burden.
68. Clozapine and Olanzapine Are Particularly Important
They are associated with comparatively high metabolic and diabetes risk.
69. Some Agents Carry Lower Metabolic Risk
The chapter particularly contrasts these with medications such as:
* aripiprazole
* ziprasidone
* lurasidone.
The appropriate choice still depends upon the patient’s overall clinical circumstances.
70. Metabolic Monitoring Is Part of Good Psychiatric Prescribing
Before and during relevant antipsychotic treatment, consider:
WEIGHT
BLOOD PRESSURE
FASTING GLUCOSE
LIPIDS
FAMILY HISTORY OF DIABETES/CARDIOVASCULAR DISEASE
Type 1 Diabetes and Eating Disorders
71. Eating Disorders Have a Special Manifestation in Type 1 Diabetes
A patient can manipulate insulin as a weight-control behaviour.
72. Insulin Omission Can Function as Purging
Reducing or omitting insulin promotes weight loss but carries potentially severe consequences, including poor glycaemic control and diabetic ketoacidosis.
73. Recurrent DKA or Unexpectedly Poor Glycaemic Control Should Raise the Question
Particularly when accompanied by:
* body-image concerns
* eating-disorder symptoms
* unexplained insulin omission.
Polycystic Ovary Syndrome
74. PCOS Is an Endocrine Syndrome, Not Simply “Ovarian Cysts”
The chapter uses a diagnostic framework requiring exclusion of alternative causes followed by features involving:
* ovulatory dysfunction
* hyperandrogenism
* polycystic ovarian morphology.
Normal-appearing ovaries do not necessarily exclude PCOS when the other criteria are met.
So a normal BMI does not exclude significant metabolic dysfunction.
77. Hyperinsulinaemia Can Increase Free Androgens
Insulin can:
* stimulate ovarian androgen production
* reduce hepatic sex-hormone-binding globulin.
The result is greater biologically available testosterone.
78. PCOS Can Present Through Several Different Routes
Including:
IRREGULAR MENSTRUATION
INFERTILITY
HIRSUTISM
ACNE
ALOPECIA
or metabolic problems.
PCOS and Mental Health
79. Depression Is More Common in PCOS
The relationship is likely multifactorial rather than attributable to a single hormone.
80. Anxiety Symptoms Are Also Increased
Psychological responses to:
* hirsutism
* acne
* weight changes
* fertility problems
* menstrual disturbance
may contribute alongside biological mechanisms.
81. Insulin Resistance May Be a Shared Mechanism
This again reinforces the broader chapter theme:
METABOLIC FUNCTION ↔ BRAIN FUNCTION
Valproate and PCOS
82. Valproate Is an Important Psychiatric Connection
The chapter describes an association between valproate treatment and increased PCOS risk.
This matters particularly in women receiving valproate for bipolar disorder.
83. But Do Not Assume Medication Explains Everything
Menstrual abnormalities may precede treatment in some women with bipolar disorder.
Possible contributors include:
* medication
* underlying vulnerability
* metabolic dysfunction
* shared biological mechanisms.
Hyperprolactinaemia
84. Prolactin Is Produced by the Anterior Pituitary
Its most familiar physiological role is stimulating milk production.
85. Dopamine Normally Inhibits Prolactin
This relationship is extremely important in psychiatry:
DOPAMINE ┤ PROLACTIN
Therefore:
BLOCK D₂ → REMOVE INHIBITION → PROLACTIN ↑
86. Antipsychotics Can Therefore Cause Hyperprolactinaemia
This is a predictable pharmacological consequence of dopamine blockade in the tuberoinfundibular pathway.
87. Risperidone Is Particularly Important
Although atypical antipsychotics generally have less effect on prolactin than typical agents, risperidone is a major exception.
88. Aripiprazole Is Different
Because of its partial D2 agonist properties, switching to or sometimes using aripiprazole can reduce antipsychotic-associated prolactin elevation in appropriate patients.
Clinical Features of Hyperprolactinaemia
89. Think Reproductive and Sexual Symptoms
Possible manifestations include:
AMENORRHOEA
GALACTORRHOEA
INFERTILITY
LOW LIBIDO
GYNAECOMASTIA
SEXUAL DYSFUNCTION
90. A Pituitary Mass Produces Additional Clues
Particularly:
HEADACHE + VISUAL DISTURBANCE
These symptoms should broaden the assessment beyond medication adverse effects.
91. Not Every Elevated Prolactin Is Caused by an Antipsychotic
Other possibilities include:
* prolactinoma
* pregnancy
* breastfeeding
* hypothyroidism
* hypothalamic disease
* other medications
* physiological stress.
The Diagnostic Framework
92. When Psychiatric Symptoms Appear, Ask Four Questions
A. Could this be a primary psychiatric disorder?
B. Could an endocrine disease be producing the psychiatric syndrome?
C. Could psychiatric medication have caused endocrine dysfunction?
D. Could endocrine treatment have produced the psychiatric symptoms?
This framework prevents premature diagnostic closure.
93. Pay Particular Attention to Temporal Relationships
Ask:
What changed first?
* mood?
* medication?
* steroid dose?
* lithium exposure?
* menstrual cycle?
* weight?
* thyroid function?
* metabolic parameters?
Chronology often reveals causality better than the symptom list alone.
94. Look for Discordance
A psychiatric diagnosis becomes less secure when something does not fit.
Examples:
DEPRESSION + COLD INTOLERANCE + BRADYCARDIA
→ think hypothyroidism.
PANIC + WEIGHT LOSS + TREMOR + TACHYCARDIA
→ think hyperthyroidism.
NEW MANIA + RECENT HIGH-DOSE PREDNISONE
→ think corticosteroid effect.
DEPRESSION + HYPOTENSION + HYPONATRAEMIA
→ think adrenal insufficiency.
AMENORRHOEA + GALACTORRHOEA + ANTIPSYCHOTIC
→ check prolactin.
IRREGULAR MENSES + HIRSUTISM + METABOLIC DYSFUNCTION
→ consider PCOS.
95. Treatment Resistance Is Sometimes a Diagnostic Signal
Before repeatedly escalating psychiatric treatment, reconsider whether:
* thyroid disease
* adrenal disease
* metabolic dysfunction
* medication adverse effects
* another medical condition
is contributing.
96. The Central Lesson
Endocrine psychiatry can be understood as a set of interacting feedback loops:
HYPOTHALAMUS
↓
PITUITARY
↓
ENDOCRINE GLAND
↓
HORMONE
↓
BRAIN + BODY + BEHAVIOUR
↺
Psychiatric illness can alter these systems.
Endocrine disease can alter mental state.
Psychiatric medications can disrupt endocrine function.
Endocrine medications can produce psychiatric syndromes.
So the psychiatrist’s task is not merely to recognise:
Hyperglycaemia, inflammation, vascular changes, stress systems and neuronal insulin signalling may contribute to the biological connection between diabetes and depression. The direction of causality therefore cannot simply be reduced to “the patient is depressed because they have diabetes.”
Holmes finds another clue.
Depression can change not only the disease but the experience of the disease.
A patient with depression may report substantially greater fatigue, pain and other diabetes-related symptoms even when objective measures such as HbA1c do not fully explain the difference.
This creates an important psychiatric distinction:
For someone using insulin, the distinction can become frighteningly difficult. Repeated false alarms may encourage catastrophising; repeated genuine hypoglycaemia may eventually lead someone to dismiss symptoms that require urgent action.
Holmes next enters the Family Chamber.
A young child with type 1 diabetes cannot independently manage repeated glucose checks, insulin, food and exercise. Parents become part of the treatment system.
But adolescence changes the equation.
The developmental drive towards independence can collide directly with parental anxiety and the demands of diabetes:
“CHECK YOUR GLUCOSE.”
“TAKE YOUR INSULIN.”
“WATCH WHAT YOU EAT.”
What appears medically as non-adherence may sometimes represent a developmental struggle over autonomy, identity and control.
Another corridor contains the eating disorders.
Here Holmes discovers an especially dangerous possibility in insulin-dependent diabetes: deliberately reducing or withholding insulin to influence weight.
Further along lies another interconnected triangle:
DEPRESSION ↔ OBESITY ↔ TYPE 2 DIABETES
Shared behavioural, metabolic, inflammatory and neuroendocrine pathways make the relationship far more complex than a simple linear chain.
Then Holmes enters the psychiatric pharmacy.
The detective suddenly realises psychiatry itself can alter the metabolic machinery.
Some antipsychotics produce substantial weight gain and increase metabolic risk. Other psychotropic medications can also contribute to weight gain.
So psychiatric treatment must ask not only:
“Is this medication helping the mind?”
but also:
“What is it doing to the body?”
Finally Holmes reaches the most important room: Collaborative Care.
There is no separate psychiatric machine and diabetes machine.
One team monitors:
A1c • BLOOD PRESSURE • CHOLESTEROL • DEPRESSION
while simultaneously addressing medication, diet, exercise, smoking, motivation and problem solving.
The mystery is solved.
Diabetes and psychiatric illness do not merely coexist.
The source emphasises this reciprocal relationship: respiratory illnesses commonly involve dyspnoea, hypoxia and disturbed sleep, while severe disease can produce major functional impairment; together these can increase vulnerability to anxiety, depression and other psychiatric problems.
Asthma provides perhaps the clearest example. It is a genuine inflammatory airway disorder characterised by obstruction, inflammation, hyper-responsiveness and airway remodelling. Yet stress and emotion can themselves precipitate bronchoconstriction, while anxiety can alter the perception of airway obstruction. Some anxious patients may interpret benign respiratory sensations as evidence of an impending attack; others may underestimate dangerous obstruction and delay treatment.
The psychiatrist therefore must avoid two opposite mistakes:
“IT’S ALL ANXIETY.”
and
“IT’S ALL THE LUNGS.”
Both can be dangerous.
Holmes next enters the COPD chamber, where breathlessness has become persistent rather than episodic. Depression, anxiety and panic are common, while disability and frightening dyspnoea progressively narrow the patient’s world. Avoidance produces deconditioning; deconditioning makes activity harder; breathlessness increases; fear grows.
The vicious cycle becomes:
DYSPNOEA → FEAR → AVOIDANCE → DECONDITIONING → MORE DYSPNOEA
Pulmonary rehabilitation attempts to reverse this spiral by combining physical exercise with education, self-management, nutrition and psychosocial support.
Further along lies cystic fibrosis, where psychiatric care confronts a different burden: not simply breathlessness but the relentless demands of chronic disease management. Airway clearance, medications, nutrition, repeated appointments, infections, transitions from paediatric to adult services, fertility concerns and eventually decisions around transplantation can occupy enormous portions of a person’s life. Depression and anxiety may then impair the very adherence required to preserve physical health.
Holmes then reaches respiratory failure.
Here the psychiatric picture can change abruptly. Hypoxia and hypercapnia can disturb cerebral function, while critical illness, mechanical ventilation and intensive care create vulnerability to delirium, depression, anxiety and post-traumatic stress symptoms.
But perhaps the most deceptive corridor contains disorders in which respiratory symptoms are real even when conventional pulmonary pathology cannot adequately explain them.
Chronic hyperventilation produces hypocapnia. Vocal cord dysfunction can suddenly obstruct inspiration and mimic asthma. Tic cough and somatic cough disorder can produce persistent coughing. Sighing dyspnoea can create repeated sensations of unsatisfying breathing.
The historical word “psychogenic” becomes increasingly inadequate because Holmes discovers no clean border between mind and body. Respiratory sensations emerge from interactions between:
Here another clue emerges: sometimes psychiatric symptoms arise not from respiratory disease but from its treatment.
Corticosteroids can produce insomnia, irritability, depression, hypomania, mania, psychosis, cognitive impairment and occasionally delirium. Higher acute doses are particularly associated with manic or hypomanic presentations, whereas prolonged lower-dose exposure may be more associated with depression. Theophylline and β₂-agonists may contribute to anxiety and agitation.
The final lesson becomes clear.
The psychiatrist’s question is not simply:
“Does this patient have lung disease or anxiety?”
It is:
“HOW ARE THE LUNGS, BRAIN, BREATHING BEHAVIOUR, EMOTIONS AND TREATMENTS INTERACTING IN THIS PERSON?”
Key Takeaways
1. Respiratory Disease and Psychiatry Are Bidirectionally Connected
Respiratory illness can influence mental health.
Mental health can influence respiratory symptoms, illness behaviour and disease management.
2. Four Features Are Particularly Important
Respiratory disorders frequently involve:
DYSPNOEA
HYPOXIA
POOR SLEEP
INSOMNIA
All may contribute to psychiatric symptoms.
3. Functional Impairment Also Matters
Severe respiratory disease can restrict:
* exercise
* employment
* social activity
* independence
* sleep
* everyday functioning.
This increases vulnerability to depression and anxiety.
4. Psychiatric Comorbidity Can Worsen Respiratory Outcomes
It can influence:
* adherence
* symptom interpretation
* smoking
* physical activity
* treatment seeking
* rehabilitation
* emergency healthcare use.
The Psychiatrist’s Role
5. Diagnose and Treat Psychiatric Comorbidity
Particularly:
* anxiety
* panic
* depression
* sleep disturbance
* cognitive impairment
* trauma-related symptoms.
6. Identify Psychosocial Triggers
Stress and emotional states can influence respiratory symptoms in some patients.
7. Address the Psychological Consequences of Chronic Illness
PSYCHIATRIC ILLNESS ↔ MEDICATION ↔ WEIGHT ↔ PHYSICAL HEALTH
One particularly important chamber contains the psychiatric dispensary. Olanzapine, clozapine, quetiapine, lithium, valproate, mirtazapine and several other psychotropics can contribute to weight gain. The psychiatrist therefore cannot simply prescribe for the mind while ignoring the metabolic consequences for the body.
Another chamber contains food, but Holmes discovers that eating is not always driven by hunger.
For some people:
DISTRESS → EATING → TEMPORARY RELIEF
Repeated often enough, food can become an emotion-regulation strategy. Binge eating, grazing and night eating may further complicate obesity, while highly palatable foods engage reward pathways that have prompted comparisons with addictive processes.
Outside the laboratory lies an even larger clue: the obesogenic environment. Calorie-dense food is inexpensive and readily available, while transport, screens, sedentary employment and energy-saving technologies progressively remove physical activity from everyday life.
Treatment must therefore be equally multidimensional.
Holmes walks through rooms devoted to nutrition, exercise, behavioural weight management, CBT, mindfulness and acceptance-based approaches, motivational interviewing, medication and bariatric surgery. None represents a universal solution.
Behavioural treatment teaches self-monitoring, goal setting, stimulus control and sustainable habit change. CBT adds an investigation of the thoughts that can transform one setback into abandonment:
“I ate one biscuit” → “I’ve ruined everything” → “I might as well give up.”
Acceptance-based approaches teach people to experience cravings and uncomfortable emotions without automatically responding through eating.
Motivational interviewing asks an even earlier question:
Is the person ready to change?
Because prescribing action to somebody still contemplating change may simply produce disengagement.
And then Holmes encounters perhaps the hardest mystery of all: maintenance. Losing weight and maintaining that loss are not the same task. Relapse and weight regain are common, meaning obesity frequently requires long-term management rather than a single successful intervention.
At the far end of the laboratory stands bariatric surgery - the most powerful long-term intervention described in the source for severe obesity. Yet even surgery does not remove psychology from the equation. Candidates require careful assessment of expectations, eating behaviour, psychiatric stability, substance use, coping and social support, while psychological monitoring remains important afterwards.
Holmes finally replaces the simplistic inscription:
Obesity is not merely about how much energy enters the body.
The real mystery is what determines that behaviour, how the body responds to it, and how sustainable change can be supported without stigma or blame.
Key Takeaways
1. Obesity Is a Major Health Condition
Obesity has substantial:
* physical
* psychological
* social
* economic
consequences.
2. BMI Remains the Most Common Measure
BMI = weight (kg) ÷ height² (m²)
3. Adult BMI Categories
Underweight: <18.5Normal: 18.5–24.9Overweight: 25–29.9Obesity class I: 30–34.9Obesity class II: 35–39.9Severe/class III obesity: ≥40
4. BMI Is an Imperfect Measure
It does not adequately distinguish:
* muscle from fat
* bone density
* fitness
* fat distribution
* broader metabolic health.
5. Waist Circumference Provides Additional Information
Central adiposity can provide useful information about metabolic risk beyond BMI alone.
6. Childhood Obesity Requires Age- and Sex-Specific Assessment
Children are assessed using BMI percentiles rather than adult cut-offs.
Why Obesity Matters
7. Obesity Affects Almost Every Organ System
Associated conditions include:
* hypertension
* dyslipidaemia
* type 2 diabetes
* coronary disease
* stroke
* fatty liver disease
* gallstones
* reflux
* osteoarthritis
* obstructive sleep apnoea
* respiratory disease
* infertility
* PCOS
* urinary incontinence
* thromboembolism
* gout
* some cancers.
8. Mental Health Is Part of the Medical Burden
The source’s whole-body diagram on page 4 explicitly includes depression alongside cardiovascular, respiratory, metabolic, gastrointestinal and musculoskeletal complications.
Obesity should therefore never be conceptualised as purely cosmetic.
9. Childhood Obesity Predicts Later Risk
Children with obesity are more likely to develop adult obesity and associated cardiometabolic complications.
10. Appropriate Medical Assessment Matters
Depending upon presentation, assessment may include:
* lipids
* blood pressure
* glucose
* thyroid function
* vitamin status
* assessment for obstructive sleep apnoea.
Why Does Obesity Develop?
11. The Basic Energy Equation Is Correct but Incomplete
At the most fundamental level:
ENERGY IN > ENERGY EXPENDITURE → ENERGY STORAGE
But this tells us little about why the imbalance develops.
“WHAT MATTERS TO YOU, AND WHAT CHANGE ARE YOU READY TO MAKE?”
Medical and Surgical Treatment
100. Medication Can Be Added to Lifestyle Intervention
The chapter discusses pharmacological treatment for appropriate patients alongside diet, activity and behavioural management.
101. The Source Discusses Several Weight-Loss Medicines
These include:
* orlistat
* phentermine/topiramate
* naltrexone/bupropion
* phentermine
* liraglutide.
Because obesity pharmacotherapy has evolved rapidly, the chapter’s medication list should be understood in the context of when the source was written rather than as a current prescribing guideline.
102. GLP-1 Signalling Is Particularly Important
The source discusses liraglutide acting through GLP-1 pathways involved in appetite regulation and notes promising evidence emerging for the GLP-1 agonist class.
103. Medication Does Not Eliminate the Maintenance Problem
Weight regain can occur when pharmacotherapy is discontinued.
Obesity therefore often requires ongoing management.
Bariatric Surgery
104. Surgery Is the Most Effective Long-Term Treatment Described for Severe Obesity
The source considers candidates including:
BMI >40
or
BMI >35 + obesity-related disease
within the criteria used in the chapter.
105. Bariatric Procedures Work Through Different Mechanisms
The diagram on page 37 illustrates:
GASTRIC BAND
SLEEVE GASTRECTOMY
ROUX-EN-Y GASTRIC BYPASS
BILIOPANCREATIC DIVERSION
and demonstrates the distinction between restrictive and malabsorptive approaches.
106. Surgery Can Produce Major Medical Benefits
Potential improvements include:
* metabolic syndrome
* hypertension
* sleep apnoea
* fatty liver disease
* hypercholesterolaemia
* reflux
* quality of life.
107. Psychological Assessment Is Part of Bariatric Care
Assessment should explore:
* motivation
* expectations
* understanding of surgery
* ability to make lifestyle changes
* psychiatric symptoms
* substance use
* eating behaviour
* social support
* coping strategies.
108. Psychiatric Instability May Need Treatment Before Surgery
The source identifies concerns such as:
* unstable depression
* psychosis
* suicidal ideation
* active bulimia
* active substance misuse.
The aim is optimisation and safety rather than simply excluding people because they have a psychiatric diagnosis.
109. Surgery Does Not End the Need for Mental Healthcare
Postoperative issues may include:
* mood symptoms
* changing relationships
* body-image adjustment
* excess skin
* recurrence of disordered eating
* substance use
* medication absorption changes.
110. Alcohol Problems Require Particular Attention After Bariatric Surgery
The source describes increased risk of alcohol-use disorders following some procedures.
111. Suicide Risk Also Requires Monitoring
The chapter reports increased suicide risk after bariatric surgery, reinforcing the importance of longitudinal psychiatric follow-up.
112. Psychotropic Pharmacokinetics May Change
For example, absorption of some antidepressants may change following Roux-en-Y gastric bypass.
Medication response therefore requires reassessment after surgery.
The Central Clinical Framework
113. Never Reduce Obesity to Willpower
The clinically useful question is not:
“Why can’t this person just eat less?”
Ask instead:
What biological, psychological, environmental and behavioural mechanisms are maintaining the current pattern?
114. Assess the Biological System
Consider:
* genetics
* metabolic health
* appetite
* sleep
* medications
* physical illness
* mobility.
115. Assess Eating Behaviour
Look for:
* hunger-driven eating
* emotional eating
* binge eating
* grazing
* night eating
* loss of control
* food cues.
116. Assess Mental Health
Consider:
* depression
* anxiety
* trauma
* severe mental illness
* body image
* stigma
* substance use.
117. Assess the Environment
Ask about:
* food availability
* work
* activity opportunities
* finances
* social environment
* routine
* environmental triggers.
118. Assess Medication
Particularly ask:
IS THE TREATMENT OF THE PSYCHIATRIC DISORDER CONTRIBUTING TO THE METABOLIC PROBLEM?
119. Assess Readiness
Before prescribing behaviour change, determine whether the person is:
The most familiar example is irritable bowel syndrome. Recurrent abdominal pain interacts with defecation and changes in stool frequency or form. But beneath the symptoms Holmes finds multiple mechanisms: altered motility, visceral hypersensitivity, stress-system dysregulation, immune activity, early-life experiences and altered central processing.
Further along lies centrally mediated abdominal pain syndrome, where abdominal pain becomes continuous or nearly continuous and substantially disrupts daily life despite the absence of another condition adequately explaining it.
Another corridor leads to functional chest pain, where recurrent retrosternal pain persists after appropriate cardiac, oesophageal and reflux pathology has been excluded. Here again, hypersensitivity, hypervigilance, autonomic arousal and altered central processing may amplify the experience of bodily signals.
One of the most dangerous traps in this entire hall is written above a doorway:
“THE TESTS ARE NORMAL, SO IT MUST BE IN YOUR HEAD.”
Holmes refuses to enter.
Functional symptoms are not imaginary symptoms.
Instead, the clinical task is to explain how altered sensation, processing, attention, stress physiology and gut–brain communication can produce genuine suffering without requiring visible structural damage.
The psychiatrist therefore becomes neither the clinician who proves that “nothing is wrong” nor the final destination after medicine has failed. Psychiatry becomes part of integrated gastrointestinal care.
The tools are familiar - antidepressants, CBT, mindfulness, relaxation, interpersonal approaches, psychodynamic therapy, hypnotherapy and selected neuromodulators - but the therapeutic relationship may be just as important.
The investigation ultimately leads Holmes to a deceptively simple principle:
Validate the symptom. Explain the mechanism. Reduce unnecessary investigation. Treat psychiatric comorbidity. Restore function.
The gut and brain are not separate suspects.
They are partners in the same conversation.
Key Takeaways
1. The Gut and Brain Communicate Bidirectionally
The central concept is:
BRAIN ↔ GUT
Neither organ simply acts upon the other.
2. The Modern Model Goes Beyond the Gut–Brain Axis
The broader construct is the:
BRAIN–GUT–MICROBIOME AXIS
It incorporates interactions involving:
* CNS
* enteric nervous system
* autonomic nervous system
* HPA axis
* immune system
* endocrine signalling
* intestinal microbiome.
3. Communication Occurs Through Multiple Pathways
Think:
NEURAL + IMMUNE + HORMONAL + MICROBIAL
These pathways interact continuously.
4. The Biopsychosocial Model Is Particularly Appropriate for GI Disorders
Biological, psychological and social influences should not be considered competing explanations.
6. Peptic Ulcer Disease Provides a Historical Warning
Peptic ulcer disease was once considered strongly psychosomatic before the importance of Helicobacter pylori was recognised.
Therefore:
“WE CANNOT SEE THE MECHANISM” ≠ “THERE IS NO MECHANISM.”
7. Organic and Functional Disease Can Coexist
A patient with inflammatory bowel disease can achieve mucosal healing and still experience significant functional gastrointestinal symptoms.
One diagnosis does not exclude the other.
Inflammatory Bowel Disease
8. The Two Major Forms of IBD Are
CROHN DISEASE
and
ULCERATIVE COLITIS
9. Crohn Disease Can Affect the Entire GI Tract
It may involve anywhere from:
MOUTH → ANUS
10. Ulcerative Colitis Is Confined to the Colon
This provides an important distinction from Crohn disease.
11. IBD Is an Inflammatory Disorder
The chapter conceptualises its pathogenesis as an interaction between:
GENETIC SUSCEPTIBILITY
MICROBIOME
INAPPROPRIATE IMMUNE RESPONSE
12. IBD Symptoms Extend Beyond Diarrhoea
Patients may experience:
* abdominal pain
* diarrhoea
* rectal bleeding
* fatigue
* malnutrition
* weight loss
* anaemia
* joint symptoms
* skin manifestations.
13. IBD Can Profoundly Affect Quality of Life
The burden comes not merely from intestinal inflammation but also:
* fatigue
* cognitive symptoms
* extraintestinal manifestations
* treatment burden
* psychological consequences.
14. Depression and Anxiety Are Common in IBD
Mood disorders may affect as many as approximately:
1 IN 3
patients with IBD.
15. Psychiatric Symptoms Often Increase During IBD Relapse
Anxiety and depression tend to be particularly prominent in:
SEVERE
and
ACTIVE
IBD.
16. Depression and IBD May Have a Bidirectional Relationship
The model is not simply:
IBD → DEPRESSION
It may involve:
IBD ↔ DEPRESSION
17. Psychiatric Comorbidity Can Affect Symptom Experience
Depression and anxiety may contribute to:
* visceral hypersensitivity
* increased bowel symptom burden
* fatigue
* insomnia
* cognitive problems
* impaired coping.
18. Visceral Hypersensitivity Is a Key Concept
The gastrointestinal system can become unusually sensitive to internal stimuli.
Signals that might normally produce little discomfort can be experienced as significant pain.
19. IBD Can Be Associated With Cognitive Difficulties
Reported problems include impairment in:
* processing speed
* short-term memory
* aspects of verbal functioning.
Systemic inflammation may contribute.
20. Anxiety in IBD Can Become Highly Symptom-Specific
Patients may develop fear of:
* nausea
* vomiting
* eating
* diarrhoea
* faecal incontinence.
21. Fear of Incontinence Can Produce Avoidance
A patient may begin avoiding:
* public transport
* unfamiliar locations
* queues
* social activities
* places without immediately accessible toilets.
This can resemble or contribute to agoraphobic behaviour.
22. PTSD Can Occur in IBD
Potential traumatic experiences include:
* severe disease
* repeated hospitalisation
* invasive procedures
* surgery
* frightening exacerbations.
Treatment and IBD
23. Treating Depression Can Improve More Than Mood
Effective treatment may improve:
* self-management
* relationships
* social support
* engagement with treatment teams
* quality of life.
The source also describes associations with improved IBD outcomes.
24. Psychological Treatments Have a Role
Approaches discussed include:
* CBT
* supportive therapy
* relaxation
* mindfulness
* gut-directed hypnotherapy.
25. Psychotropics Can Be Chosen According to the Clinical Problem
For example:
MIRTAZAPINEmay be useful where nausea, poor appetite or weight difficulties are prominent.
TCAsmay target pain, visceral hypersensitivity, IBS symptoms and insomnia.
SNRIsmay help depression, anxiety and chronic pain.
Steroid-Induced Psychiatric Illness
26. Corticosteroids Can Produce Psychiatric Adverse Effects
These may include:
* anxiety
* agitation
* mood disturbance
* confusion
* psychosis.
27. Always Review Medication When Mental State Suddenly Changes
In someone receiving treatment for a physical illness:
NEW PSYCHIATRIC SYMPTOMS → REVIEW NEW MEDICATIONS
before assuming a primary psychiatric disorder.
28. The Chapter’s Clinical Case Demonstrates This Clearly
A woman receiving intravenous hydrocortisone for severe ulcerative colitis developed:
CONFUSION → AGITATION → ANXIETY → PARANOIA
and was diagnosed with steroid-induced psychosis.
The colonoscopy image on page 8 shows markedly inflamed, friable and ulcerated rectal mucosa, emphasising that the patient had severe genuine inflammatory disease at the same time as a treatment-induced psychiatric complication.
Functional Gastrointestinal Disorders
29. Functional GI Symptoms Are Real Symptoms
The absence of a visible structural lesion does not make symptoms imaginary.
This principle is fundamental.
30. Functional GI Disorders Are Common
More than 25 separate disorders have been described within this broad category.
31. IBS Is the Most Prevalent Functional GI Disorder
The chapter reports a global prevalence exceeding:
10%
with a female predominance.
Irritable Bowel Syndrome
32. The Core Symptom of IBS Is Recurrent Abdominal Pain
The Rome IV framework links pain to bowel function.
33. Rome IV Requires Recurrent Abdominal Pain
The chapter’s table on page 10 specifies pain on average at least:
1 DAY PER WEEK
during the previous 3 months.
34. The Pain Must Be Associated With at Least Two Features
* related to defecation
* change in stool frequency
* change in stool form.
Symptoms should have begun at least 6 months before diagnosis.
35. IBS Can Be Classified by Predominant Stool Pattern
The figure on page 10 divides IBS into:
IBS-C - constipation predominant
IBS-D - diarrhoea predominant
IBS-M - mixed bowel habits
IBS-U - unclassified.
36. IBS Is Not Only About the Bowel
Associated symptoms may include:
* fatigue
* headache
* dysmenorrhoea
* dyspareunia.
37. Psychiatric Comorbidity Is Very Common in IBS
Important associations include:
* major depression
* panic disorder
* generalised anxiety disorder
* PTSD
* somatic symptom disorder.
38. More Than Half of Patients With IBS May Have Psychiatric Comorbidity
The chapter reports that psychiatric disorders occur in over half of patients in some samples.
39. IBS and Psychiatric Illness Are Again Bidirectional
Think:
DISTRESS ↔ GI SYMPTOMS
Psychological distress can influence bowel symptoms.
Chronic bowel symptoms can produce psychological distress.
40. Early-Life Experiences May Be Relevant
The source discusses associations between later visceral sensitivity and:
* adverse early-life experiences
* childhood sexual abuse
* other significant stressors.
These are risk factors and associations, not simple deterministic causes.
41. Multiple Mechanisms May Contribute to IBS
These include:
* brain–gut dysregulation
* HPA-axis dysregulation
* altered GI motility
* visceral hypersensitivity
* immune reactivity
* infection
* genetic susceptibility
* psychosocial factors.
Centrally Mediated Abdominal Pain Syndrome
42. CAPS Is Dominated by Pain
The core presentation is:
CONTINUOUS OR NEARLY CONTINUOUS ABDOMINAL PAIN
with significant interference in everyday functioning.
43. CAPS Differs From IBS
In IBS, pain is related to bowel function.
In CAPS, pain has:
NO OR ONLY OCCASIONAL RELATIONSHIP
to physiological events such as:
* eating
* defecation
* menstruation.
44. CAPS Must Impair Function
This may affect:
* work
* education
* relationships
* intimacy
* social activity
* leisure
* caregiving.
45. The Pain Is Not Feigned
This is explicitly part of the Rome IV criteria described in the chapter.
That distinction is essential.
46. Other Explanations Must Be Considered
The pain should not be better explained by another:
* structural GI disorder
* functional GI disorder
* medical condition.
47. Central Pain Processing Appears Important
The chapter describes alterations involving areas including:
* somatosensory cortex
* insula
* anterior cingulate cortex.
48. Functional Disorders Often Cluster
A patient with chronic functional abdominal pain may also have:
* fibromyalgia
* chronic fatigue
* generalised pain
* other functional symptoms.
The Investigation Cycle
49. Repeated Negative Investigations Can Become Part of the Problem
The patient may move through:
SYMPTOMS
→ INVESTIGATION
→ NORMAL RESULT
→ CONTINUING UNCERTAINTY
→ ANOTHER DOCTOR
→ MORE INVESTIGATIONS
→ MORE ANXIETY
→ MORE SYMPTOMS
50. The Chapter Illustrates This Cycle Directly
The diagram on page 16 shows:
CHRONIC UNEXPLAINED SYMPTOMS
→ DISENFRANCHISED PATIENT
→ MULTIPLE INVESTIGATIONS
→ POOR TREATMENT OUTCOMES
→ MULTIPLE DIFFERENT PHYSICIANS
→ back to chronic unexplained symptoms.
51. More Testing Is Not Always More Reassuring
Repeated investigations may inadvertently communicate:
“WE STILL THINK SOMETHING DANGEROUS HAS BEEN MISSED.”
This can reinforce fear and symptom vigilance.
52. The Cycle Can Be Interrupted
The chapter emphasises:
TIME + EMPATHY + VALIDATION
Functional Chest Pain
53. Functional Chest Pain Is Recurrent Retrosternal Pain
It occurs without an adequate structural explanation after appropriate investigation.
54. Appropriate Exclusions Are Important
The source describes excluding:
* GERD
* eosinophilic oesophagitis
* major oesophageal motor disorders.
Investigations may include:
* upper endoscopy
* biopsy
* reflux testing
* oesophageal manometry.
55. Functional Chest Pain Is Not a Diagnosis Made by Ignoring Cardiac Disease
Potentially dangerous cardiac explanations must first be considered appropriately.
56. Oesophageal Hypersensitivity May Contribute
Mechanical or chemical stimuli may be experienced more intensely than expected.
57. Stress Systems May Amplify Symptoms
Relevant systems include:
ANS
and
HPA AXIS
58. Central Processing Also Matters
The brain’s interpretation of oesophageal sensory input can influence the intensity of the experienced symptom.
59. Psychological Comorbidity Is Common
The chapter reports psychological comorbidity in up to:
61%
of patients with functional chest pain.
Presentation Bias
60. Depression Does Not Always Present as “I Feel Depressed”
Patients may present with:
* abdominal pain
* nausea
* fatigue
* bowel disturbance
* sleep problems
* multiple physical complaints.
61. This Can Produce “Presentation Bias”
When the patient’s presentation is predominantly physical, clinicians may fail to recognise underlying:
DEPRESSION
or
ANXIETY
62. The More Physical Symptoms, the Greater the Probability of Psychological Distress
The table on page 20 shows a striking gradient:
Number of physical symptoms
Mood or anxiety disorder
0–1
4%
2–3
18%
4–5
31%
6–8
52%
9+
78%
This does not mean multiple symptoms are “psychological”; it means increasing somatic symptom burden should also prompt thoughtful assessment of emotional distress.
The Gut–Brain Axis
63. Stress Can Influence GI Physiology
Stress can alter:
* motility
* pain thresholds
* inflammation
* autonomic activity
* HPA-axis activity.
64. The Gut Can Influence the Brain
Signals originating in the gastrointestinal tract can influence:
* arousal
* emotion
* vigilance
* pain processing
* anxiety.
65. The Diagram on Page 23 Captures the Central Model
External and internal stressors influence the brain and neuroendocrine response.
Signals then interact with:
HPA AXIS
AUTONOMIC NERVOUS SYSTEM
SENSORY MODULATION
and the:
GASTROINTESTINAL TRACT
Feedback then returns towards the CNS.
The essential message is:
BIDIRECTIONAL COMMUNICATION
Visceral Sensitisation
66. Both Peripheral and Central Factors Can Increase Symptom Burden
Peripheral factors include:
* hormones
* injury
* infection
* diet.
Central or psychosocial influences include:
* chronic stress
* coping difficulties
* psychiatric illness
* adverse experiences.
67. The Figure on Page 25 Shows Two Routes Towards Greater Symptom Burden
One involves increased:
AFFERENT NERVE EXCITATION
The other involves reduced:
AFFERENT NERVE INHIBITION
Both can move the person from mild towards severe symptoms.
Therapeutic Relationship
68. The Therapeutic Relationship Is Part of Treatment
The psychiatrist should:
* elicit beliefs
* understand concerns
* explore expectations
* demonstrate empathy
* correct misunderstandings
* provide education
* negotiate treatment collaboratively.
69. Validate Before Reframing
A useful sequence is:
LISTEN → VALIDATE → EXPLAIN → CONNECT → TREAT
not:
NORMAL TEST → PSYCHIATRIC REFERRAL
70. Never Communicate “It’s All in Your Head”
That framing:
* invalidates the patient
* misunderstands functional illness
* damages trust
* increases stigma
* can make psychiatric referral harder.
71. Psychiatry Should Not Represent Rejection From Gastroenterology
The message should instead be:
“We understand your symptoms better when we treat the gut and brain together.”
72. Symptom Diaries Can Be Useful
Patients can record:
* pain
* bowel movements
* stool consistency
* menstruation
* diet
* lifestyle
* stressors.
This can reveal patterns and create opportunities for psychoeducation and CBT.
Chronic Illness
73. Cure Is Not Always the Immediate Goal
For chronic functional symptoms, a more realistic goal may be:
BETTER FUNCTION DESPITE SYMPTOMS
74. Excessive Diagnostic Investigation Can Be Harmful
Once an adequate diagnostic assessment has been completed, repeated investigations may:
* reinforce fear
* expose patients to procedural risk
* increase healthcare dependence
* perpetuate uncertainty.
75. Health-Promoting Behaviour Should Be Reinforced
The focus gradually shifts from:
“FIND THE HIDDEN DISEASE”
towards:
“RESTORE LIFE AND FUNCTION.”
Psychopharmacology
76. Antidepressants Can Help FGIDs Even Without Major Depression
This is an important concept.
They may function as:
NEUROMODULATORS
rather than merely “antidepressants”.
77. Their Effects Can Occur Throughout the Gut–Brain Axis
Relevant neurotransmitters include:
* serotonin
* noradrenaline
* CRF
* endogenous opioid pathways.
78. TCAs Can Help Chronic Visceral Pain
Potential benefits include:
* central pain modulation
* peripheral effects
* slowing gastrointestinal transit.
79. One Detail in the Source Requires Careful Reading
The chapter states that slowing GI transit may be valuable for IBS-C, but later recommends TCAs particularly where diarrhoea predominates. Physiologically, slowing transit aligns more naturally with diarrhoea-predominant symptoms.
For the podcast, the important source-supported principle is:
TCAs CAN MODULATE PAIN AND SLOW GI TRANSIT.
80. SSRIs Have Different GI Effects
SSRIs can stimulate gastrointestinal motility.
They may therefore be particularly useful where:
* anxiety
* phobic symptoms
* somatisation
* constipation
are prominent.
81. SNRIs Can Be Useful for Pain
Their combined serotonergic and noradrenergic activity makes them relevant where:
PAIN + ANXIETY/DEPRESSION
coexist.
82. Mirtazapine Has a Useful GI Profile
It may be particularly helpful when the clinical picture includes:
* nausea
* reduced appetite
* weight loss
* insomnia.
83. The Chapter Reports a Low NNT for Antidepressants in IBS
The reported:
NNT ≈ 3.2
for overall improvement illustrates why psychotropics may be useful beyond treating formal psychiatric diagnoses.
84. Benzodiazepines Have a Limited Long-Term Role
They may reduce acute anxiety but chronic use is limited by:
* sedation
* cognitive effects
* tolerance
* dependence
* addiction risk.
FGIDs are usually chronic disorders, making long-term benzodiazepines particularly problematic.
Psychological Treatment
85. There Is No Single Best Psychological Therapy for Every Patient
Treatment should be matched to:
* formulation
* symptoms
* psychiatric comorbidity
* preferences
* motivation
* availability.
86. Engagement Is Fundamental
Even an effective therapy is unlikely to work if the patient experiences referral as:
“The doctors have given up and think I’m imagining this.”
Acute coronary syndromes include unstable angina, myocardial infarction and cardiac arrest.
4. Traditional CAD Risk Factors Remain Fundamental
Important factors include:
* family history
* male sex
* hypertension
* hyperlipidaemia
* diabetes
* obesity
* sedentary behaviour
* smoking.
Psychiatric factors operate alongside these rather than replacing them.
5. Depression Is Strongly Associated With CAD
Depression is associated with an almost twofold increased risk of developing CAD.
Among patients who already have CAD, depression is associated with approximately double the risk of adverse coronary outcomes, including MI, revascularisation and death.
The graph on page 3 of the chapter strikingly demonstrates progressively poorer five-year cardiac survival after MI with increasing depression severity.
6. Depression May Affect the Heart Through Behaviour
Potential pathways include:
DEPRESSION → SMOKING
DEPRESSION → PHYSICAL INACTIVITY
DEPRESSION → SOCIAL ISOLATION
DEPRESSION → POOR ADHERENCE
These behaviours independently influence cardiovascular risk.
7. Biological Pathways May Also Contribute
Proposed mechanisms include:
* HPA-axis dysregulation
* elevated cortisol
* altered autonomic activity
* endothelial effects
* platelet activation
* increased thrombotic activity.
The relationship is therefore not explained purely by lifestyle.
8. Anxiety Is Common in CAD
Anxiety may affect prognosis independently of depression.
Potential mechanisms again include:
* smoking
* inactivity
* autonomic activation
* reduced adherence
* physiological stress responses.
9. PTSD and Cardiovascular Disease Can Also Interact
PTSD has been associated with:
* CAD
* heart failure
* peripheral vascular disease
* cerebrovascular disease.
Cardiac disease itself can also become the traumatic event.
10. Cardiac Illness Can Cause PTSD
A myocardial infarction can be experienced as:
A LIFE-THREATENING EVENT ARISING FROM WITHIN THE BODY
The patient may subsequently become hypervigilant to:
* heart rate
* chest sensations
* breathlessness
* palpitations
* bodily changes.
Cardiac interventions and ICD shocks can also become traumatic experiences.
33. Persistent Tachycardia After Starting Clozapine Deserves Attention
Tachycardia can be common with clozapine, but when accompanied by systemic or cardiac symptoms clinicians should consider myocarditis rather than automatically attributing it to a benign medication effect.
34. Infective Endocarditis Demonstrates the Need for Integrated Addiction Care
Injection drug use can cause infective endocarditis.
Optimal treatment requires:
CARDIOLOGY + CARDIAC SURGERY + ADDICTION/PSYCHIATRY
Treating the valve infection without treating the substance-use disorder leaves a major driver of recurrence unaddressed.
For opioid-use disorder, medications discussed include:
* buprenorphine
* methadone
* naltrexone.
The chapter emphasises addiction treatment as a core part of managing injection-related endocarditis.
36. Psychiatry Needs Basic ECG Literacy
A systematic ECG assessment considers:
RATE → RHYTHM → INTERVALS → AXIS
Clinical context comes first.
37. Know What the Waves Represent
P wave = atrial depolarisation
QRS = ventricular depolarisation
T wave = ventricular repolarisation
This becomes particularly important when understanding psychotropic cardiac effects.
38. Bradycardia Is <60 bpm
Potential causes include:
* athletic conditioning
* medications
* hypothyroidism
* ischaemia
* conduction disease
* electrolyte abnormalities
* increased vagal tone.
Lithium can contribute to sinus-node dysfunction and bradycardia.
39. Tachycardia Is >100 bpm
Psychotropics with anticholinergic effects can cause sinus tachycardia.
These include:
* TCAs
* many antipsychotics
* MAOIs
* anticholinergic medications.
Clozapine commonly causes tachycardia.
40. Rhythm Can Be Classified Simply
Ask two questions:
Is the QRS narrow or wide?
and:
Is the rhythm regular or irregular?
This rapidly narrows the differential diagnosis.
41. Atrial Fibrillation Is Irregularly Irregular
AF involves disorganised atrial electrical activity.
Therefore:
NO ORGANISED ATRIAL CONTRACTION
IRREGULARLY IRREGULAR VENTRICULAR RESPONSE
Major consequences include stroke and heart failure.
42. Psychological Distress and AF Can Interact
AF is associated with:
* depression
* anxiety
* psychological distress
* reduced quality of life.
Negative emotional states have also been associated with increased likelihood of AF episodes.
43. QT Is About Ventricular Electrical Recovery
The QT interval encompasses:
VENTRICULAR DEPOLARISATION + REPOLARISATION
Because QT varies with heart rate, clinicians use:
QTc
the corrected QT interval.
44. QTc Prolongation Matters Because of Torsades de Pointes
Torsades de pointes is a potentially lethal:
POLYMORPHIC VENTRICULAR TACHYCARDIA
QT prolongation is a marker of increased risk, but QTc alone does not perfectly predict who will develop torsades.
45. Think About the Whole QT Risk Profile
Important risk factors include:
* older age
* female sex
* congenital long-QT syndrome
* structural cardiac disease
* bradycardia
* hypokalaemia
* hypomagnesaemia
* hypocalcaemia
* renal impairment
* hepatic impairment
* acute illness
* multiple QT-prolonging drugs
* pharmacokinetic interactions.
The medication is only one component.
46. Psychotropic Polypharmacy Can Increase Risk
Always consider whether the patient is simultaneously receiving:
* antipsychotics
* antidepressants
* antiarrhythmics
* antibiotics
* antifungals
* antiemetics
* methadone
* other QT-prolonging agents.
Risk can accumulate.
47. Antipsychotics Differ in QT Effects
The chapter identifies aripiprazole and lurasidone as having particularly low QT-prolongation liability.
Greater concern is described with agents including:
* thioridazine
* ziprasidone
* iloperidone.
But individual patient risk factors remain crucial.
48. Citalopram Has Dose-Related QTc Effects
Citalopram produces greater QT prolongation than most other SSRIs.
However, QT effects should be weighed against psychiatric benefit rather than prompting automatic discontinuation or dose reduction.
49. Sertraline Has Been Extensively Studied in Cardiac Patients
Among antidepressants, sertraline has substantial evidence in cardiac populations and is commonly considered a useful first-line SSRI when depression coexists with cardiac disease.
50. SSRIs Can Affect Bleeding
SSRIs reduce platelet serotonin storage and can increase bleeding risk.
Be particularly alert when combined with:
ANTIPLATELETS
or
ANTICOAGULANTS
or
NSAIDs
51. TCAs Affect Cardiac Conduction
TCAs can cause:
* QRS widening
* conduction delay
* heart block
* tachycardia
* orthostatic hypotension
* ventricular arrhythmias in overdose.
This explains why TCAs require particular caution in cardiac disease.
52. Lithium Has Several Potential Cardiac Effects
Lithium has been associated with:
* bradycardia
* sinus-node dysfunction
* sinus block
* sinus arrest
* AV conduction abnormalities.
Risk assessment must also consider lithium-induced hypothyroidism and interacting medications.
53. Methadone Is Important in QT Assessment
Methadone has a clear association with:
QTc PROLONGATION
and
TORSADES DE POINTES
The chapter describes buprenorphine as a safer alternative from a QT perspective.
54. But Cardiac Monitoring Should Not Become a Barrier to Addiction Treatment
The clinical task is balancing:
CARDIAC SAFETY
with
ACCESS TO LIFE-SAVING OPIOID-USE-DISORDER TREATMENT
rather than allowing monitoring requirements to inadvertently prevent treatment.
55. Cardiac Devices Matter to Psychiatry
Important devices include:
* permanent pacemakers
* implanted cardioverter-defibrillators
* cardiac resynchronisation therapy.
Psychiatrists treating complex cardiac patients should understand their basic functions.
56. ICD Shocks Can Be Psychologically Traumatic
Repeated shocks may produce:
* anticipatory anxiety
* hypervigilance
* avoidance
* PTSD symptoms.
The device saves life but can itself become associated with fear.
57. Do Not Automatically Blame Patients for Device Problems
Lead migration was historically labelled “twiddler’s syndrome”, implying patient manipulation.
The chapter highlights evidence questioning this assumption.
This is an important example of how psychiatric labels can contribute to diagnostic stigma.
58. Cardiac Disease Can Masquerade as Psychiatric Illness
Assessment therefore demands more than a conventional psychiatric interview. Holmes must examine the medical record, medications, laboratory investigations, neurological findings, cognition, collateral information, the reason the treating team requested help and - crucially - the patient’s own experience of illness.
Treatment is similarly integrated. Psychotropic prescribing must account for organ function, drug interactions and medical vulnerability, while psychotherapy may address fear, disability, pain, changing roles, adherence, loss, dying and adaptation.
By the end, Holmes removes the old signs from the hospital.
There is no separate Mind Hospital and Body Hospital.
There is only:
THE PATIENT
Key Takeaways
1. Consultation-Liaison Psychiatry Sits at the Medicine–Psychiatry Interface
C-L psychiatry specialises in psychiatric assessment and treatment within the context of physical illness.
Its central question is:
“How are the medical and psychiatric problems interacting?”
2. “Psychosomatic” Does Not Mean Imaginary
Historically, psychosomatic became associated with the dismissive idea that unexplained symptoms were “all in your head”.
That is misleading.
The original concept concerns relationships between:
PSYCHE ↔ SOMA
or:
MIND ↔ BODY
3. Modern Medicine Rejects a Simple Mind–Body Split
Physical illness can cause psychiatric symptoms.
Psychiatric illness can influence physical health.
Medical treatment can produce psychiatric complications.
Psychological responses can influence symptoms, behaviour and treatment.
Social circumstances affect both.
Therefore:
BIOLOGY ↔ PSYCHOLOGY ↔ SOCIAL CONTEXT
4. The History of Psychosomatic Medicine Is Important
Ancient physicians already recognised that emotional states could produce bodily responses.
The chapter describes Hippocrates observing associations such as:
FEAR → SWEATING
SHAME → PALPITATIONS
The modern terminology changed dramatically, but recognition of mind–body interaction is ancient.
5. Historical Explanations Were Often Wrong
Medicine previously attributed unexplained symptoms to theories including:
* hysteria
* uterine disease
* “reflex neurosis”
* nervous fluid
* spinal irritation
* neurasthenia.
Some patients underwent unnecessary and harmful treatments because erroneous theories were treated as established fact.
An important clinical lesson follows:
UNEXPLAINED DOES NOT MEAN UNREAL.
And:
CURRENTLY UNEXPLAINED DOES NOT MEAN MEDICALLY EXCLUDED FOREVER.
6. Symptom Presentation Is Influenced by Culture
The ways people understand and express illness change across historical periods and cultures.
Historical presentations dominated by paralysis and dramatic neurological symptoms later shifted towards presentations such as:
* fatigue
* chronic pain
* other bodily symptoms.
Illness occurs biologically, but its experience and expression are also socially shaped.
7. Freud Helped Reconnect Psyche and Soma
Psychodynamic theories emphasised how psychological conflict could be expressed through physical symptoms.
Some historical explanations were subsequently unsupported, but they helped medicine reconsider the possibility that emotion, meaning and bodily experience interact.
8. Early Psychosomatic Theories Often Became Too Specific
Some theorists attempted to link:
SPECIFIC PERSONALITY → SPECIFIC CONFLICT → SPECIFIC DISEASE
For example, particular personality styles were historically proposed to cause particular gastrointestinal or cardiovascular diseases.
The evidence did not support such simple one-to-one relationships.
9. Stress Became a More General Biological Model
Later theories examined how stress activates physiological systems rather than assuming one specific psychological conflict causes one specific disease.
Important systems include:
* autonomic nervous system
* hypothalamic-pituitary-adrenal axis
* endocrine pathways
* cardiovascular responses
* immune pathways.
10. The Biopsychosocial Model Integrates These Systems
George Engel’s biopsychosocial framework conceptualised illness through interacting:
This becomes particularly important in ICD-11, where personality disorder is primarily classified by severity - mild, moderate or severe - followed by trait qualifiers.
The chapter also challenges therapeutic pessimism. Personality is relatively enduring, but it is not necessarily immutable. Psychotherapy, relationships, learning and increasing self-awareness can alter how people regulate emotion, pursue goals, understand themselves and relate to others.
Holmes therefore leaves the mansion with a different question from the one with which he entered.
Not:
“What kind of difficult person is this?”
But:
“What enduring pattern is operating here, how did it develop, what function does it serve, and where might greater flexibility become possible?”
Key Takeaways
1. Personality Is Not the Same as Personality Disorder
Personality describes relatively enduring patterns in how someone:
* experiences themselves
* experiences other people
* regulates emotions
* behaves
* pursues goals
* adapts to the environment.
Having unusual or extreme traits does not automatically indicate pathology.
The chapter specifically emphasises that even extreme temperament variants need not produce personality disorder.
2. Think in Terms of Adaptation
A useful overarching model is:
PERSONALITY = TEMPERAMENT × CHARACTER × DEVELOPMENT × EXPERIENCE × SELF-AWARENESS
Personality is not merely something a person has.
It is part of the system through which they continually adapt.
and associated with significant dysfunction or impairment.
The problem is therefore not simply possessing a trait, but being unable to adapt that trait sufficiently to changing circumstances.
4. Temperament and Character Are Different
One of the chapter’s major conceptual distinctions is between temperament and character.
Temperament refers more closely to biologically influenced emotional and behavioural tendencies.
Character involves higher-order development of goals, values, identity and self-regulation.
The chapter’s psychobiological model therefore argues that temperament influences how someone reacts, while character helps determine how those reactions are regulated and integrated.
5. Four Temperament Dimensions
The Temperament and Character Inventory describes:
* Novelty Seeking
* Harm Avoidance
* Reward Dependence
* Persistence
Different combinations create different behavioural styles.
None is inherently pathological.
6. Three Character Dimensions
The model adds:
* Self-Directedness
* Cooperativeness
* Self-Transcendence
Low self-directedness and cooperativeness are particularly associated with personality-disorder symptoms across diagnostic clusters.
A useful conceptual distinction is therefore:
TRAIT EXTREMITY ≠ PERSONALITY DISORDER
The crucial issue is whether the person’s overall personality system can regulate those traits adaptively.
7. Personality Emerges From Biology and Experience
Personality development reflects interactions among:
But the chapter stresses that these clusters and individual diagnoses overlap substantially.
11. Categorical Diagnosis Has Limitations
Traditional diagnosis asks:
DISORDER PRESENT OR ABSENT?
This is clinically convenient.
But personality traits usually exist on continua.
Drawing a categorical line through a continuous characteristic inevitably introduces some arbitrariness.
It also struggles with patients who have significant features of several disorders without fitting neatly into one prototype.
12. Dimensional Models Ask a Different Question
Instead of:
“Which box?”
they ask:
“How severe is the dysfunction, and what traits describe it?”
This may better reflect the reality that personality characteristics exist along dimensions.
13. ICD-11 Makes Severity Central
ICD-11 represents an important conceptual shift.
First assess personality-disorder severity:
MILD → MODERATE → SEVERE
Then describe prominent traits.
The emphasis moves away from accumulating categorical labels and towards understanding the degree and nature of personality dysfunction.
14. ICD-11 Trait Domains
The dimensional formulation can include:
* Negative Affectivity
* Detachment
* Dissociality
* Disinhibition
* Anankastia
with a borderline pattern qualifier also available.
These describe how personality dysfunction manifests rather than assuming every patient belongs to a discrete personality “type”.
15. Assess Self and Interpersonal Functioning
A particularly useful clinical framework is to examine:
SELF
Identity
Who am I?
Self-direction
Can I establish and pursue coherent goals?
INTERPERSONAL
Empathy
Can I understand another person’s experience?
Intimacy
Can I develop reciprocal, enduring relationships?
Personality pathology often becomes most visible in these domains.
16. Ego-Syntonicity Can Complicate Assessment
Many personality traits are experienced as:
“THIS IS JUST WHO I AM.”
rather than:
“SOMETHING IS HAPPENING TO ME.”
This differs from many episodic psychiatric disorders.
The patient may therefore present because of:
* depression
* anxiety
* relationship breakdown
* substance misuse
* occupational difficulties
* self-harm
* interpersonal crisis
rather than complaining directly about their personality.
17. Defence Mechanisms Can Become Habitual
The chapter revisits psychodynamic formulations in which defensive strategies become entrenched components of personality.
Examples discussed include:
Projection → paranoid patterns
Acting out → antisocial patterns
Fantasy → schizoid patterns
The broader lesson is more important than memorising pairings:
A DEFENCE THAT PROTECTS IN ONE CONTEXT MAY BECOME MALADAPTIVE WHEN USED EVERYWHERE.
18. Assessment Requires Longitudinal Thinking
Do not diagnose personality disorder from behaviour during a single crisis.
Ask:
Has this pattern existed for years?
Does it occur across settings?
What happens in relationships?
What was functioning like before the current illness?
How does the patient understand themselves?
What do collateral sources describe?
Personality is fundamentally longitudinal.
19. State Can Be Mistaken for Trait
Depression may make someone appear chronically pessimistic.
Mania may produce impulsivity or grandiosity.
PTSD may produce mistrust.
Psychosis may produce suspiciousness.
Substances may produce instability.
Autism may affect social interaction.
Therefore:
STATE ≠ TRAIT
until longitudinal assessment demonstrates otherwise.
20. Comorbidity Is Common
Personality disorders frequently coexist with:
* mood disorders
* anxiety disorders
* substance-use disorders
* eating disorders
* trauma-related disorders
* other personality disorders.
Multiple categorical personality diagnoses may partly reflect weaknesses in the boundaries between existing categories.
21. Assessment Tools Can Help - But Do Not Replace Formulation
The chapter discusses structured interviews and personality measures including:
* structured diagnostic interviews
* personality inventories
* dimensional trait measures
* Temperament and Character Inventory.
These can organise information.
They do not replace clinical history, longitudinal observation and contextual formulation.
22. Treatment Requires More Than Symptom Suppression
Medication may help particular co-occurring symptoms or disorders.
But there is no medication that simply removes a personality disorder.
Treatment aims at deeper capacities such as:
EMOTIONAL REGULATION
SELF-UNDERSTANDING
FLEXIBILITY
RELATIONSHIP FUNCTION
GOAL-DIRECTED BEHAVIOUR
SELF-REGULATION
23. Psychotherapy Is Central
Different disorders and presentations may benefit from different structured approaches.
But across therapies, the deeper objective is often similar:
RIGID PATTERN → AWARENESS → ALTERNATIVE RESPONSE → PRACTICE → GREATER FLEXIBILITY
The therapeutic relationship itself may also reveal the patient’s characteristic interpersonal patterns.
24. Personality Is Enduring - Not Frozen
This distinction is fundamental.
Personality traits can be stable enough to recognise across decades while still remaining capable of modification through:
* maturation
* relationships
* psychotherapy
* learning
* environmental change
* deliberate self-reflection.
The chapter’s developmental diagrams reinforce this idea: temperament influences possible pathways, but does not dictate a single inevitable character outcome.
25. Holmes’ Personality Formulation
Rather than stopping at a diagnostic label, ask:
What are the dominant traits?
How severe is the dysfunction?
How does the person experience themselves?
How do they relate to others?
What happens when they are stressed?
Which patterns repeatedly create problems?
How did those patterns develop?
What function have they served?
Where is there capacity for flexibility and change?
The central principle becomes:
“Personality disorder is not simply about who someone is - it is about where enduring ways of being have become rigid enough to prevent adaptation.”
